Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 10867. Отображено 100.
12-01-2012 дата публикации

Acetals as perfuming ingredients

Номер: US20120010114A1
Принадлежит: Individual

Acetal derivatives of 2,2,3,6-tetramethyl-1-cyclohexane/ene-carbaldehyde of formula (I): for use in the perfumery industry as well as the resulting compositions or articles containing one or more of these compounds. In formula (I), one dotted line indicates the presence of a carbon-carbon single or double bond and the other dotted line indicates the presence of a carbon-carbon single bond, R 1 represents a hydrogen atom or a methyl or ethyl group; and each R, taken alone, simultaneously or independently, represents a C 1-3 alkyl or alkenyl group, or the R groups, taken together, represent a C 2-6 hydrocarbon group optionally including an oxygen atom.

Подробнее
02-02-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120027796A1
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)).

Подробнее
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
01-03-2012 дата публикации

Alkylamido Compounds and Uses Thereof

Номер: US20120053244A1
Принадлежит: Individual

Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

Подробнее
01-03-2012 дата публикации

Methods of Treating Hair Related Conditions

Номер: US20120053245A1
Принадлежит: Individual

Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.

Подробнее
19-04-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120095075A1
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure:

Подробнее
03-05-2012 дата публикации

Films and particles

Номер: US20120107365A1

Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses.

Подробнее
10-05-2012 дата публикации

N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation

Номер: US20120115915A1
Принадлежит: Harvard College

Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

Подробнее
17-05-2012 дата публикации

No-Carrier-Added Nucleophilic [F-18] Fluorination of Aromatic Compounds

Номер: US20120123120A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Phenyliodonium ylide derivatives substituted with electron donating as well as electron withdrawing groups on the aromatic ring are shown for use as precursors in aromatic nucleophilic substitution reactions. The iodonium ylide group is substituted by nucleophiles such as halide ions to provide the corresponding haloaryl derivatives. No-carrier-added [F-18]fluoride ion exclusively substitutes the iodonium ylide moiety in these derivatives and provides high specific activity F-18 labeled fluoro derivatives. Protected L-dopa-6-iodonium ylide derivative have been synthesized as a precursors for the preparation of no-carrier-added 6-[F-18]fluoro-L-dopa. The iodonium ylide group in this L-dopa.derivative is nucleophilically substituted by no-carrier-added [F-18]fluoride ion to provide a [F-18]fluoro intermediates which upon acid hydrolysis yielded 6-[F-18]fluoro-L-dopa.

Подробнее
12-07-2012 дата публикации

Polymers bearing pendant pentafluorophenyl ester groups, and methods of synthesis and functionalization thereof

Номер: US20120178891A1

A one pot method of preparing cyclic carbonyl compounds comprising an active pendant pentafluorophenyl ester group is disclosed. The cyclic carbonyl compounds can be polymerized by ring opening methods to form ROP polymers comprising repeat units comprising a side chain pentafluorophenyl ester group. Using a suitable nucleophile, the pendant pentafluorophenyl ester group can be selectively transformed into a variety of other functional groups before or after the ring opening polymerization.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
06-09-2012 дата публикации

Palmarumycin based inhibitors of thioredoxin and methods of using same

Номер: US20120226031A1
Автор: Garth Powis, Peter Wipf

Embodiments of the present invention relate to inhibitors of thioredoxin. Certain embodiments relate to palmarumycin based compounds and methods of using the same. Such compounds may be useful in inhibiting the overexpression of thioredoxin, inhibiting tumor growth and treating cancer.

Подробнее
13-09-2012 дата публикации

Polycarbonates for delivery of drugs and methods of preparation thereof

Номер: US20120232018A1

A cyclic carbonate monomer has the formula (2): wherein i) t and t′ are integers independently having a value from 0 to 6 wherein t′ and t cannot both be zero, ii) each Q 1 is a monovalent radical independently selected from the group consisting of hydrogen, halides, alkyl groups comprising 1 to 30 carbons, and aryl groups comprising 6 to 30 carbon atoms, iii) L′ is a divalent linking group comprising one or more carbons, and iv) S′ is a steroidal group.

Подробнее
27-09-2012 дата публикации

Aryloxyanilide imaging agents

Номер: US20120244073A1
Принадлежит: Individual

The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

Подробнее
13-12-2012 дата публикации

Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex

Номер: US20120316066A1
Принадлежит: Intrexon Corp

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

Подробнее
20-12-2012 дата публикации

4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Номер: US20120322875A1
Принадлежит: Individual

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.

Подробнее
24-01-2013 дата публикации

Lactide Production from Thermal Depolymerization of PLA with applications to Production of PLA or other bioproducts

Номер: US20130023674A1
Принадлежит: Individual

Methods and systems are disclosed for producing lactide, which can be used for PLA production or other valuable bioproducts. PLA is heated to undergo thermal depolymerization to recover lactide. The lactide can be used for PLA production or other valuable bioproducts.

Подробнее
14-03-2013 дата публикации

Novel cationic lipids and methods of use thereof

Номер: US20130064894A1
Принадлежит: PROTIVA BIOTHERAPEUTICS INC

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Подробнее
21-03-2013 дата публикации

Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon

Номер: US20130071328A1
Принадлежит: UNIVERSITY OF SOUTHERN CALIFORNIA

This invention discloses a series of novel propynoic acid carbamoyl methyl-amides (PACMAs), methods for synthesizing the PACMAs and pharmaceutical compositions containing the PACMAs. These novel compounds and compositions show cytotoxicity in cancer cells and are useful as lead compounds for anti-cancer drugs or pharmaceutical agents. This invention also discloses treatment methods that uses the PACMAs and pharmaceutical compositions as well as methods for promoting the release and nuclear localization of the transcription factor Nrf2. 4. A compound according to claim 1 , wherein said compound further contains a substituent capable of being used in a biological or medical diagnostic imagining technique to quantify or identify associated biomarker proteins.5. A compound according to claim 3 , wherein said compound further contains a substituent capable of being used in a biological or medical diagnostic imagining technique to quantify or identify associated biomarker proteins.7. A pharmaceutical composition comprising any of the compounds of to and a pharmaceutically acceptable carrier.8. A method for treatment a cancer subject claim 3 , comprising the step of:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'administering to a person in need of said treatment method an effective amount of the pharmaceutical composition according to .'}9. A method of claim 8 , where the cancer is: breast cancer claim 8 , ovarian cancer claim 8 , prostate cancer claim 8 , colon cancer claim 8 , brain cancer claim 8 , pancreatic cancer claim 8 , skin cancer claim 8 , lung cancer claim 8 , and multiple myeloma.10. A method for promoting the release and nuclear localization of the transcription factor Nrf2 comprising the step of:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'administering an effective amount of the pharmaceutical compositions according to .'}10. A biological or medical diagnostic imaging technique claim 8 , comprising:{'claim-ref': [{'@idref': 'CLM-00004', 'claims 4 ...

Подробнее
28-03-2013 дата публикации

NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS

Номер: US20130079293A1

Isolated compounds from refined fractions and compositions containing the compounds are provided by the present invention. refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention. 10. The compound of claim 9 , wherein Ris H.11. The compound of claim 9 , wherein{'sup': '1', 'Ris H;'}{'sup': 2', '3, 'each of Rand Rare Me; and'}subscript n is 10.1514. A pharmaceutical composition for treating a neurodegenerative disease or neuropathological condition in a subject claims 1 , the composition comprising a compound of any one of - and a pharmaceutically acceptable carrier or excipient.16Adelostemma gracillimum. A method of preparing a refined fraction claims 1 , the method comprising:{'i': 'Adelostemma gracillimum', 'contacting herb with an alcohol selected from the group consisting of methanol and ethanol, to form an alcohol extract;'}contacting the alcohol extract with an organic solvent to form an organic solvent fraction; and{'i': 'Adelostemma gracillimum', 'contacting the organic solvent fraction with a petroleum ether to form the refined fraction.'}17. The method of claim 16 , further comprising:{'i': 'Adelostemma gracillimum', 'eluting a first fraction of the refined fraction from a resin column with a solution of about 30% ethanol in water;'}eluting a second fraction from the resin column with a solution of about 60% ethanol in water; andeluting a third fraction from the resin column with a solution of about 96% ethanol in water.18Adelostemma gracillimum. An refined fraction prepared by the method of .19Adelostemma gracillimum. An refined fraction prepared by the method of .20Adelostemma gracillimum. A method of improving memory in a subject claim 17 , ...

Подробнее
04-04-2013 дата публикации

COMPOSITION FOR THE TREATMENT OF ARTHRITIS CONTAINING A DIBENZO-P-DIOXIN DERIVATIVE AS THE ACTIVE INGREDIENT

Номер: US20130084330A1
Принадлежит: LIVECHEM, INC.

Disclosed is a composition for treating arthritis containing a dibenzo-p-dioxin derivative as an active ingredient. This dibenzo-p-dioxin derivative is very effective in inhibiting NF-kB and AP-1 activity, alleviates the symptoms of degenerative arthritis and rheumatoid arthritis without irritating the skin or causing side effects, and can continue to exhibit improvement effects for a considerable period of time after discontinuation of treatment. Additionally, when the dibenzo-p-dioxin derivative is contained in liposomes, the composition of the invention exhibits much greater effects on treating arthritis by absorption through skin, and thus is useful for the treatment of degenerative arthritis and rheumatoid arthritis. 2. The method according to claim 1 , wherein each R in Formulas 1 to 10 is independently hydrogen claim 1 , methyl claim 1 , acetyl or oleoyl.3. The method according to claim 1 , wherein each R in Formulas 1 to 10 is independently hydrogen.4. The method according to claim 1 , wherein the total weight of the two or more selected compounds ranges from 0.2 to 2.0 wt % of the total weight of the composition.5. The method according to claim 1 , wherein the total weight of the two or more selected compounds ranges from 0.5 to 1.5 wt % of the total weight of the composition.6. The method according to claim 1 , wherein the composition is provided in a form selected from the group consisting of an ointment claim 1 , a lotion claim 1 , a cream claim 1 , a gel claim 1 , a skin emulsion claim 1 , a skin suspension claim 1 , a patch claim 1 , and a spray.7. The method according to claim 1 , wherein the composition further comprises a liposome carrying the composition.8. The method according to claim 7 , wherein the liposome comprises multi-lamella vesicles.9. The method according to claim 7 , wherein the liposome comprises unilamella vesicles.10. The method according to claim 1 , wherein the composition is applied in a dose of 1-1000 μg/cmper day.11. The method ...

Подробнее
04-04-2013 дата публикации

KETAL LACTONES AND STEREOSPECIFIC ADDUCTS OF OXOCARBOXYLIC KETALS WITH TRIMETHYLOL COMPOUNDS, POLYMERS CONTAINING THE SAME, METHODS OF MANUFACTURE, AND USES THEREOF

Номер: US20130085201A1
Принадлежит: SEGETIS, INC.

Ketal lactones of and methods for making such ketal lactones are disclosed. Also described are methods for making isolated cis- and trans-stereoisomers of hydroxyester ketals of oxocarboxylic acids and polymers having ketal units of such stereoisomers within the polymer backbone. 4. A polymer composition comprising a polymer and a compound of .11. A polymer composition comprising a polymer and a compound of .14. A polymer composition comprising a polymer and a compound of .17. A polymer composition comprising a polymer and the combination of .21. A polymer of claim 18 , further comprising another polyester unit derived from a polyhydric alcohol having from 2 to 6 hydroxyl groups claim 18 , a C1-36 aliphatic or C6-36 aromatic dicarboxylic or tricarboxylic acid or its reactive derivative claim 18 , a hydroxylated carboxylic acid or its ester or lactone claim 18 , a hydroxyl-terminated linear or branched polyether claim 18 , a polyester polyol claim 18 , a polyurethane polyol claim 18 , a polysaccharide claim 18 , a poly(3-hydroxyalkanoate) claim 18 , a polylactate claim 18 , a polyglycolide claim 18 , a poly(co-lactate/glycolate) claim 18 , or a combination thereof.23. A polymer of claim 18 , comprising two to six of hydroxyl groups claim 18 , isocyanate groups claim 18 , (meth)acryloyl groups claim 18 , or (meth)allyl groups.24. A polymer of claim 18 , further comprising an additional claim 18 , different polymer claim 18 , a polymer additive claim 18 , or a combination thereof.25. An article comprising a polymer of .26. A foam comprising any of the polymers or compositions thereof of .31. A polymer composition of claim 30 , wherein the polymer further comprises units derived from the living polymerization in the further presence of another lactone claim 30 , a lactide claim 30 , glycolide claim 30 , bis-lactone claim 30 , dioxanone claim 30 , dioxepanone monomer claim 30 , trimethylene carbonate claim 30 , or dimethylene carbonate.32. An article comprising the ...

Подробнее
25-04-2013 дата публикации

Compounds, Compositions, And Methods For Reducing Or Eliminating Bitter Taste

Номер: US20130101684A1
Принадлежит: CHROMOCELL CORPORATION

The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product. 710.-. (canceled)1355.-. (canceled)5661112. The composition of any one of - claims 1 , or claims 1 , further comprising a bitter tastant.576111256. The composition of any one of - claims 1 , claims 1 , or claims 1 , wherein the composition further comprises one or more components selected from the group consisting of: NaCl claims 1 , sodium lactate and sugar.58611125657. The composition of any one of - claims 1 , claims 1 , claims 1 , or claims 1 , wherein the composition is found in a food product or a consumer product.5961112. The composition of any one of - claims 1 , or claims 1 , wherein the composition further comprises a pharmaceutically active ingredient claims 1 , and optionally claims 1 , a bitter tastant.60. The composition of claim 59 , wherein the pharmaceutically active ingredient is bitter.61. The composition of or claim 59 , wherein the pharmaceutically active ingredient or bitter tastant is a potassium salt.62. The composition of any one of claim 59 , or claim 59 , wherein the bitter tastant is a potassium salt claim 59 , and wherein the potassium salt is potassium chloride or potassium lactate.6361112. A method of use of the composition of any one of - claims 1 , or claims 1 , wherein the method comprises:(a) providing a comestibly acceptable carrier; and{'claim-ref': {'@idref': 'CLM-00001', 'claims 1'}, 'b': '8', '(b) adding to the comestibly acceptable carrier, a composition as described in any of - or combinations thereof.'}64. The method of claim 63 , wherein the method further comprises adding a bitter tastant to the comestibly acceptable carrier.65. The ...

Подробнее
09-05-2013 дата публикации

Process for the manufacture of a cyclic diester of an alpha-hydroxyacid

Номер: US20130116448A1
Принадлежит: SOLVAY SA

Process for the manufacture of a cyclic diester of an alpha-hydroxyacid comprising heating the alpha-hydroxyacid at a temperature from 100 to 250° C. in the presence of at least one polyol and of at least one catalyst selected from the group consisting carboxylates and alkoxides of Ti, Zr, Al and Sn. 1. A process for the manufacture of a cyclic diester of an alpha-hydroxyacid , comprising heating an alpha-hydroxyacid at a temperature from 100 to 250° C. in the presence of at least one polyol and of at least one catalyst selected from the group consisting carboxylates and alkoxides of Ti , Zr , Al and Sn.2. The process according to claim 1 , wherein said alpha-hydroxyacid is selected from the group consisting of lactic acid claim 1 , glycolic acid claim 1 , glutaric acid claim 1 , mandelic acid claim 1 , malic acid claim 1 , citric acid claim 1 , and tartaric acid.3. The process according to claim 1 , wherein said heating is conducted at a temperature from 150 to 240° C.4. The process according to claim 1 , wherein said heating is conducted under a pressure equal to or lower than 500 mbar.5. The process according to claim 1 , wherein said heating is initiated at atmospheric pressure claim 1 , then continues under a progressive vacuum until a pressure of from 10 to 200 mbar is attained.6. The process according to claim 1 , wherein said polyol is selected from the group consisting of ethylene glycol claim 1 , propylene glycol claim 1 , diethylene glycol claim 1 , glycerol claim 1 , erythritol claim 1 , mannitol claim 1 , sorbitol claim 1 , xylitol claim 1 , maltitol claim 1 , lactitol claim 1 , and volemitol.7. The process according to claim 1 , wherein said polyol is added in an amount of from 2 to 50 mol % of the alpha-hydroxyacid.8. The process according to claim 1 , wherein said catalyst is selected from the group consisting of carboxylates and alkoxides of titanium claim 1 , zirconium claim 1 , aluminum and tin claim 1 , particularly from titanium alkoxides.9. The ...

Подробнее
30-05-2013 дата публикации

AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE

Номер: US20130137743A1
Принадлежит: Genzyme Corporation

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described. 4. (canceled)5. The salt of claim 3 , wherein at least 99% by weight of the salt is in a single crystalline form.6. (canceled)7. The hemitartrate salt of claim 1 , wherein the hemitartrate salt is L-hemitartrate.89-. (canceled)10. The salt of claim 3 , wherein the single crystalline form is characterized by at least two major x-ray powder diffraction peaks at 2θ angles of 5.1° claim 3 , 6.6° claim 3 , 10.7° claim 3 , 11.0° claim 3 , 15.9° claim 3 , and 21.7°.1112-. (canceled)13. The salt of claim 3 , wherein the single crystalline form is characterized by major x-ray powder diffraction peaks at 2θ angles of 5.1° claim 3 , 6.6° claim 3 , 10.7° claim 3 , 11.0° claim 3 , 15.9° claim 3 , and 21.7°.14. The salt of claim 3 , wherein the single crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of 5.1° claim 3 , 6.6° claim 3 , 10.7° claim 3 , 11.0° claim 3 , 13.3° claim 3 , 15.1° claim 3 , 15.9° claim 3 , 16.5° claim 3 , 17.6° claim 3 , 18.6° claim 3 , 18.7° claim 3 , 19.0° claim 3 , 20.2° claim 3 , 21.7° claim 3 , and 23.5°.15. (canceled)17. The pharmaceutical composition of claim 16 , wherein at least 90% by weight of the salt is in a single crystalline form.1831-. (canceled)32. A method of treating a subject with Gaucher disease or Fabry disease claim 16 , or inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need ...

Подробнее
11-07-2013 дата публикации

METHOD OF PRODUCING INGENOL-3-ANGELATE

Номер: US20130177952A1
Принадлежит:

The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). 4. The method according to claim 1 , wherein the method comprises the step of:(f) selective esterification of the 3-hydroxy group of compound (II) to obtain ingenol-3-angelate (I).5. The method according to claim 2 , wherein Rrepresents hydrogen or an ether claim 2 , acetal claim 2 , ketal claim 2 , silylether claim 2 , ester claim 2 , carbonate claim 2 , or a sulfenate derived hydroxyl protective group claim 2 , and Rrepresents hydrogen or an ether claim 2 , acetal claim 2 , ketal claim 2 , silylether claim 2 , ester claim 2 , carbonate claim 2 , or a sulfenate derived hydroxyl protective group.6. The method according to claim 2 , wherein D represents an acetal claim 2 , ketal- claim 2 , diacetal- claim 2 , diketal- claim 2 , ortho ester claim 2 , silyl claim 2 , boronate or a carbonate derived dihydroxyl protective group.7. The method according to claim 2 , wherein Ris selected from the group consisting of hydrogen or [(3 claim 2 ,4-dimethoxybenzyl)oxy]methyl claim 2 , guaiacolmethyl claim 2 , 2-methoxyethoxymethyl claim 2 , tetrahydropyranyl claim 2 , tetrahydrofuranyl claim 2 , 1-ethoxyethyl claim 2 , 1-methyl-1-methoxyethyl claim 2 , allyl claim 2 , prenyl claim 2 , p-methoxybenzyl claim 2 , triphenylmethyl claim 2 , 2-(trimethylsilyl)ethoxymethyl claim 2 , triethylsilyl claim 2 , triisopropylsilyl claim 2 , tert-butyldimethylsilyl claim 2 , dimethylisopropylsilyl claim 2 , diethylisopropylsilyl claim 2 , tert-butyldiphenylsilyl claim 2 , triphenylsilyl claim 2 , acetyl claim 2 , chloroacetyl claim 2 , phenoxyacetyl or angeloyl.8. The method according to claim 2 , wherein Ris selected from the group consisting of hydrogen or [(3 claim 2 ,4-dimethoxybenzyl)oxy]methyl claim 2 , guaiacolmethyl claim 2 , 2-methoxyethoxymethyl claim 2 , tetrahydropyranyl claim 2 , tetrahydrofuranyl claim 2 , 1-ethoxyethyl claim 2 , 1-methyl-1-methoxyethyl claim 2 , allyl claim 2 , prenyl ...

Подробнее
11-07-2013 дата публикации

Esters of hexanoic acids as intermediates for the preparation of atorvastatin

Номер: US20130178636A1

The invention relates to compounds of general formula (3) wherein R 4 is allyl, 2-butyl, cyclohexyl, 3-methyl-2-butyl or 4-methyl-2-pentyl, a method for the preparation of compounds of general formula (3) and their use in the preparation of atorvastatin.

Подробнее
18-07-2013 дата публикации

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Номер: US20130184222A1
Принадлежит: AGIOS PHARMACEUTICALS, INC

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here. 2. The compound of claim 1 , wherein Ris 3-fluorophenyl.3. The compound of or claim 1 , wherein:{'sup': '1', 'Ris selected from cyclohexyl, cyclopentyl, cycloheptyl, 3,3-difluorocyclobutyl, 4,4,-difluorocyclohexyl, and bicyclo[2.2.1]heptanyl; and'}{'sup': '4', 'Ris selected from 1-(methylmethoxycarbonylamino)ethyl, 1,2,3,4-tetrahydroquinolin-1-yl, 1-ethoxycarbonylpiperidin-2-yl, 1-ethoxycarbonylpyrrolidin-2-yl, 1H-benzimidazol-1-ylmethyl, 1H-indazol-3-ylmethyl, indolin-1-ylmethyl, 1H-indol-3-ylmethyl, 1H-indol-5-ylmethyl, 1H-pyrrolo[2,3-b]pyridine-3-ylmethyl, 1H-pyrrolo[3,2-b]pyridin-3-ylmethyl, 1-methoxycarbonylpiperidin-2-yl, 1-methoxycarbonylpyrrolidin-2-yl, 2-fluoropyridin-3-ylaminomethyl, 2-imino-4-fluoropyridin-1-ylmethyl, 2-methoxyphenylaminomethyl, 2-methyl-1H-benzimidazol-1-ylmethyl, 2-methylimidazol-1-ylmethyl, 2-trifluoromethyl-1H-imidazol-1-yl, 3-cyanophenylaminomethyl, 3-fluoropyridin-2-ylaminomethyl, 3-methoxyphenylaminomethyl, 4-(1,3,4-oxadiazole-2-yl)phenylaminomethyl, 4-(dimethylaminocarbonyloxy)phenylmethyl, 4,5-dichloroimidazol-1-ylmethyl, 4-cyanophenylaminomethyl, 4-fluorophenylaminomethyl, 4-fluoropyridin-2-ylaminomethyl, 4-hydroxyphenylmethyl, 4-methoxycarbonylmorpholin-3-yl, 4-methoxycarbonylpiperazin-1-ylmethyl, 4-methoxyphenylaminomethyl, 4-methylcarbonyloxyphenylmethyl, 5-fluoropyridin-2-aminomethyl, 5-fluoropyridin-2-oxymethyl, 6-fluoropyridin-3-ylaminomethyl, benzomorpholin-4-ylmethyl, methoxycarbonylaminomethyl, methylmethoxycarbonylaminomethyl, methylphenylaminomethyl, phenylaminomethyl, pyridin-2-oxymethyl, pyridin-2-ylaminomethyl, pyridin-2-yloxymethyl, pyridin-3-oxymethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, thiazol-4-ylmethyl, and thien-2-ylmethyl.'}4. The compound of claim 1 , wherein the compound is selected from any one of Compound numbers 104 claim ...

Подробнее
01-08-2013 дата публикации

FILMS AND PARTICLES

Номер: US20130195954A1
Принадлежит:

Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. 3. The oligomer or polymer of claim 1 , wherein Ris hydrogen or methyl.4. The oligomer or polymer of claim 1 , wherein Q is oxygen.5. A composition comprising the oligomer or polymer of .6. A polymeric film or particle comprising an oligomer or polymer of .7. A polymeric particle of claim 6 , comprising a microparticle or nanoparticle.8. A polymeric particle of claim 7 , wherein the particle has a diameter between about 2 nm and 1 micron.9. The polymeric particle of comprising a first volume at a first pH claim 7 , and a second volume at a second pH claim 7 , different from the from the first pH.10. The polymeric particle of claim 9 , wherein the second volume is 1× or more greater than the first volume when the second pH is lower than the first pH.11. The polymeric particle of claim 9 , wherein the second volume is 4× or more greater than the first volume when the second pH is lower than the first pH.12. The polymeric particle of claim 9 , wherein the second volume is 8× or more greater than the first volume when the second pH is lower than the first pH.13. The polymeric particle of claim 9 , wherein the second volume is greater than the first volume and the change in volume is sufficient that the particle when within a cell during the volume change ruptures the cell or a cellular compartment.14. The polymeric particle of claim 9 , wherein the second volume is greater than the first volume and the change in volume is sufficient to cause the particle to become lodged claim 9 , embedded claim 9 , or immobilized in an anatomic location claim 9 , such as a lymph node claim 9 , airway claim 9 , cavity claim 9 , capillary claim 9 , or other tissue.15. The polymeric film or particle of claim 6 , further comprising an agent.16. The polymeric film or particle of claim 15 , wherein the ...

Подробнее
01-08-2013 дата публикации

BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION

Номер: US20130196973A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of formula (I): 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein group A is a group of formula —NRR.3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —H or —(C-C)alkyl claim 1 , and Ris —(C-C)alkyl; wherein each —(C-C)alkyl of said Rand Rgroups claim 1 , when present claim 1 , is optionally independently substituted by one to three Rgroups.4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —H or —(C-C)alkyl claim 1 , and Ris —(C-C)alkyl; wherein said —(C-C)alkyl of said Rgroup is substituted by —(C-C)cycloalkyl claim 1 , -(4- to 11-membered)heterocycloalkyl claim 1 , —(C-C)aryl claim 1 , or -(5- to 11-membered)heteroaryl; wherein each of said claim 1 , —(C-C)cycloalkyl claim 1 , -(4- to 11-membered)heterocycloalkyl claim 1 , —(C-C)aryl claim 1 , and -(5- to 11-membered)heteroaryl is optionally substituted with one to three groups independently selected from —(C-C)alkyl claim 1 , —CF claim 1 , and —C(O)OR.5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —H or —(C-C)alkyl claim 1 , and Ris —(C-C)alkyl; wherein said —(C-C)alkyl of said Rgroup is independently substituted by one to three groups selected from —(C-C)alkyl claim 1 , —O(C-C)alkyl claim 1 , —C(O)R claim 1 , —C(O)OR claim 1 , —S(O)R claim 1 , and —NHC(O)R.6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Rand Rare each independently selected from —H or —(C-C)alkyl.7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —H or —(C-C)alkyl claim 1 , and Ris —(C-C)cycloalkyl claim 1 , -(4- to 11-membered)heterocycloalkyl claim 1 , —(C-C)aryl claim 1 , and -(5- to 11-membered)heteroaryl; wherein each of the foregoing —(C-C)cycloalkyl claim 1 , -(4- to 11-membered)heterocycloalkyl claim 1 , —(C-C)aryl claim 1 ...

Подробнее
01-08-2013 дата публикации

Substituted 1,3-Dioxanes and There Uses

Номер: US20130197030A1
Принадлежит: EVOLVA SA

The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. 35-. (canceled)719-. (canceled)20. A method for treating or preventing a disorder associated with a thromboxane A2 or peroxisome proliferator-activated receptors claim 1 , the method comprising: administering to a subject an effective amount of a compound of or acceptable salts claim 1 , N-oxides claim 1 , hydrates claim 1 , or solvates thereof; and a pharmaceutically-acceptable carrier or diluent.21. The method of claim 20 , wherein the disorder is cancer.2228-. (canceled)29. The method according to claim 20 , wherein said disorder is selected from the group consisting of myocardial infarction claim 20 , thrombosis claim 20 , thrombotic disorders claim 20 , pulmonary hypertension claim 20 , atherosclerosis claim 20 , diabetic nephropathy claim 20 , retinopathy claim 20 , peripheral arterial disease claim 20 , lower limb circulation claim 20 , pulmonary embolism claim 20 , thrombus formation claim 20 , stent-triggered thrombus formation claim 20 , stent-triggered hyperplasia hyperplasia claim 20 , septic shock claim 20 , preeclampsia claim 20 , asthma claim 20 , allergic rhinitis claim 20 , tumour angiogenesis and metastasis.3034-. (canceled)35. A pharmaceutical composition comprising the compound according to and a pharmaceutically acceptable carrier.3639-. (canceled) This application claims the benefit of and claims priority from U.S. provisional Application Ser. No. 60/989,805, filed Nov. 21, 2007, U.S. provisional Application Ser. No. 60/989,806, filed Nov. 21, 2007, U.S. provisional Application Ser. No. 60/989,808, filed Nov. 21, 2007, and PCT Application No. PCT/US07 ...

Подробнее
01-08-2013 дата публикации

SALTS OF 7-AMINO-3,5-DIHYDROXYHEPTANOIC ACID ESTERS

Номер: US20130197243A1

The invention relates to salts of acids with 2-propyl esters of general formula (2) The invention also relates to a method for the preparation of salts of acids with compounds of general formula (2) and to the use thereof in the preparation of atorvastatin. 2. Salt according to wherein said organic acid is an aliphatic monocarboxylic acid claim 1 , dicarboxylic acid or polycarboxylic acid claim 1 , cycloalkene carboxylic acid claim 1 , aliphatic unsaturated carboxylic acid claim 1 , aromatic carboxylic acid claim 1 , heterocyclic carboxylic acid or sulfonic acid.3. Salt according to wherein said organic acid is chosen from the list consisting of acetic acid claim 1 , benzenesulfonic acid claim 1 , benzoic acid claim 1 , 4-bromo-benzenesulfonic acid claim 1 , 4-bromo-benzoic acid claim 1 , 4-tert-butyl-benzoic acid claim 1 , butyric acid claim 1 , citric acid claim 1 , cyclobutane carboxylic acid claim 1 , cyclohexane carboxylic acid claim 1 , cyclopentane carboxylic acid claim 1 , cyclopropane carboxylic acid claim 1 , fumaric acid claim 1 , isovaleric acid claim 1 , maleic acid claim 1 , malic acid claim 1 , malonic acid claim 1 , methanesulfonic acid claim 1 , 4-methoxy-benzoic acid claim 1 , 4-methyl-benzenesulfonic acid claim 1 , 3-methyl-benzoic acid claim 1 , nicotinic acid claim 1 , oxalic acid claim 1 , pivalic acid claim 1 , succinic acid claim 1 , tetrahydrofurane-2-carboxylic acid claim 1 , 2-thiophenecarboxylic acid claim 1 , 3-thiophenecarboxylic acid and valeric acid.6. Method according to wherein said organic acid is an aliphatic monocarboxylic acid claim 5 , dicarboxylic acid or polycarboxylic acid claim 5 , cycloalkene carboxylic acid claim 5 , aliphatic unsaturated carboxylic acid claim 5 , aromatic carboxylic acid claim 5 , heterocyclic carboxylic acid or sulfonic acid.7. Method according to wherein said organic acid is acetic acid claim 5 , benzenesulfonic acid claim 5 , benzoic acid claim 5 , 4-bromo-benzenesulfonic acid claim 5 , 4-bromo- ...

Подробнее
15-08-2013 дата публикации

HETEROATOM CONTAINING CYCLIC DIMERS

Номер: US20130209392A1
Принадлежит: NOVUS INTERNATIONAL INC.

The present invention provides cyclic dimers of alpha acids and polymers derived therefrom. Also provided are processes for preparing and methods of using the cyclic dimers and the polymers derived from the cyclic dimers. 2. The compound of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare hydrogen; n is from 1 to 10; Z is chosen from sulfur claim 1 , sulfone claim 1 , sulfoxide claim 1 , and selenium; Ris lower chain alkyl claim 1 , and R claim 1 , if present claim 1 , is hydrogen or lower chain alkyl.4. The compound of claim 3 , wherein R claim 3 , R claim 3 , R claim 3 , R claim 3 , Rand Rare hydrogen;{'sup': 6', '10, 'each of n and m is from 1 to 10; Y and Z are independently chosen from sulfur, sulfone, sulfoxide, and selenium; Rand Rare lower chain alkyl; and'}{'sup': 7', '11, 'Rand R, if present, are independently hydrogen or lower chain alkyl.'}6. The compound of claim 5 , wherein R claim 5 , R claim 5 , R claim 5 , R claim 5 , and Rare hydrogen; n is from 1 to 10; Z is chosen from sulfur claim 5 , sulfone claim 5 , sulfoxide claim 5 , and selenium; Ris lower chain alkyl claim 5 , and R claim 5 , if present claim 5 , is hydrogen or lower chain alkyl.10. The compound of claim 9 , wherein R claim 9 , R claim 9 , R claim 9 , R claim 9 , Rand Rare hydrogen;{'sup': 6', '10, 'each of n and m is from 1 to 10; Y and Z are independently chosen from sulfur, sulfone, sulfoxide, and selenium; Rand Rare lower chain alkyl; and'}{'sup': 7', '11, 'Rand R, if present, are independently hydrogen or lower chain alkyl.'}12. The compound of claim 11 , wherein the compound comprises a racemic mixture.13. The compound of claim 11 , wherein ring atoms 3 and 6 have an L configuration.14. The compound of claim 11 , wherein ring atoms 3 and 6 have an D configuration.15. The compound of claim 11 , wherein ring atoms 3 and 6 have a meso configuration.17. The compound of claim 16 , wherein R claim 16 , R claim 16 , R claim 16 , R claim 16 , and Rare hydrogen; n ...

Подробнее
15-08-2013 дата публикации

Intermediates and methods for making zearalenone macrolide analogs

Номер: US20130211103A1
Принадлежит: Eisai R&D Management Co Ltd

Disclosed herein are methods and intermediates useful in the preparation of macrolides, e.g., compounds of formula (IV) wherein R 1 -R 12 are as defined herein.

Подробнее
22-08-2013 дата публикации

Entecavir synthesis method and intermediate compound thereof

Номер: US20130217879A1
Автор: Zhiguo Zheng
Принадлежит: AUSUN PHARMATECH CO Ltd

The present invention relates to a preparation method for a medicine and an intermediate compound thereof, specifically, relates to a preparation method for entecavir, an intermediate compound thereof, and a synthesis method for the intermediate compound.

Подробнее
22-08-2013 дата публикации

INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD

Номер: US20130217899A1
Принадлежит: MAPI PHARMA LTD.

The present invention relates to processes for the preparation of (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (Fingolimod) and pharmaceutically acceptable salts thereof, and intermediates formed in such processes. 142-. (canceled)44. The process according to claim 43 , wherein step (a) is conducted in the presence of a Friedel-Crafts catalyst claim 43 , a metal salt of an organic acid claim 43 , or a protic acid claim 43 , wherein{'sub': 3', '3', '4', '4', '2', '3, 'the Friedel Crafts catalyst is selected from AlCl, FeCl, SnCl, TiCl, ZnCland BF;'}the metal salt of an organic acid is a metal triflate selected from hafnium triflate and cerium triflate; and{'sub': 2', '4', '3', '3, 'the protic acid is selected from HF, HSO, CFSOH and an ion-exchange resin which is selected from Nafion or zeolite.'}45. The process according to claim 43 , wherein the reducing agent in step (b) is NaBH.46. The process according to claim 43 , wherein the hydroxy protecting group P in compound (13A) is acetyl (COCH) claim 43 , and wherein in step (c) the protection of 3-nitro-1-(4-octylphenyl)propan-1-ol is carried out by acylation with acetic anhydride or acetyl chloride in the presence of a base.47. The process according to claim 43 , whereinthe reduction of 3-nitro-1-(4-octylphenyl)propan-1-one (12) to 3-nitro-1-(4-octylphenyl)propan-1-ol and its conversion to compound (13A) is carried out in one step without isolation of intermediates; orwherein in step (d) the bis-hydroxymethylation of compound (13A) is carried out with formaldehyde or paraformaldehyde in the presence of a base; orwherein in step (d) the bis-hydroxymethylation of compound (13A) and deprotection to compound (14) is carried out in one step without isolation of intermediates.48. The process according to claim 43 , wherein the reduction step (e) comprises hydrogenating compound (14) to Fingolimod (1) in the presence of a Pd/C catalyst.50. The process according to claim 49 , wherein step (a) is ...

Подробнее
29-08-2013 дата публикации

SKIN LIGHTENING COMPOSITIONS

Номер: US20130224137A1
Принадлежит: LASYA, INC.

Compositions and methods for lightening mammalian skin are described herein. 2. The composition of claim 1 , wherein Z is O.3. The composition of claim 1 , wherein A and B are taken together with the atoms to which they are attached to form an optionally substituted ring having from 4-9 member atoms.4. The composition of claim 1 , wherein A and B are taken to taken together with the atoms to which they are attached to form a ring having 6 member atoms.12. The composition of claim 1 , wherein the compound of formula I is 4-(tetrahydro-2H-pyran-2-yloxy)phenol.13. The composition of claim 1 , wherein the compound of formula I is present in the composition at a concentration of about 0.5 wt. % to about 10 wt. %.14. The composition of claim 1 , wherein the composition comprises an antioxidant and the antioxidant comprises at least one of ascorbic acid claim 1 , tocopherol claim 1 , butylated hydroxybenzoic acid claim 1 , butylated hydroxytoluene claim 1 , butylated hydroxyanisole claim 1 , uric acid claim 1 , gallic acid claim 1 , sorbic acid claim 1 , glutathione claim 1 , and esters and salts of any thereof.15. The composition of claim 1 , wherein the composition comprises an antioxidant and the antioxidant comprises at least one of ascorbic acid or a salt thereof claim 1 , ascorbyl phosphate or a salt thereof claim 1 , ascorbyl palmitate or a salt thereof claim 1 , tocopherol or a salt thereof claim 1 , tocopheryl acetate and sodium metabisulfite.16. The composition of claim 1 , comprising at least two antioxidants.17. The composition of claim 1 , comprising at least three antioxidants.18. The composition of claim 1 , comprising at least four antioxidants.19. The composition of claim 1 , comprising at least five antioxidants.20. The composition of claim 1 , wherein the composition comprises an antioxidant and the antioxidant is present in an amount of about 0.01 wt. % to about 3.0 wt. %.21. The composition of claim 1 , wherein the composition comprises an antioxidant ...

Подробнее
29-08-2013 дата публикации

GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE

Номер: US20130225573A1
Принадлежит: Genzyme Corporation

A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor. 183.-. (canceled)84. The method of claim 89 , wherein the glomerular disease is mesangial proliferative glomerulonephritis.85. The method of claim 89 , wherein the glomerular disease is collapsing glomerulopathy.86. The method of claim 89 , wherein the glomerular disease is proliferative lupus nephritis.87. The method of claim 89 , wherein the glomerular disease is crescentic glomerulonephritis.88. The method of claim 89 , wherein the glomerular disease is membranous nephropathy.91. The method of claim 89 , wherein Q is —O— or —C(O)—.95. The method of claim 94 , wherein Q is —O— or —C(O)—.97. The method of claim 89 , wherein Ris a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen claim 89 , cyano claim 89 , nitro claim 89 , C1-C6 alkyl claim 89 , C1-C6 haloalkyl claim 89 , C1-C6 alkylamino claim 89 , C1-C6 dialkylamino claim 89 , aryl claim 89 , aryloxy claim 89 , —OH claim 89 , C1-C6 alkoxy claim 89 , —O—[CH]—O— and —[CH]—.104. The method of claim 89 , wherein the compound is a (1R claim 89 ,2R) stereoisomer claim 89 , or a pharmaceutically acceptable salt thereof.107. The method of claim 106 , wherein the compound is a (1R claim 106 ,2R) stereoisomer claim 106 , or a pharmaceutically acceptable salt thereof. This application is a continuation of U.S. application Ser. No. 13/055,036, filed Mar. 17, 2011, which is the U.S. National Stage of International Application No. PCT/US2009/051864, filed Jul. 27, 2009, published in English, which claims the benefit under 35 U.S.C. §119 or 365 of U.S. Provisional Application No. 61/137,214, filed Jul. 28, 2008. The ...

Подробнее
29-08-2013 дата публикации

PROCESS FOR MANUFACTURING LACTIC ACID

Номер: US20130225787A1
Принадлежит: Purac Biochem BV

A process for the preparation of lactic acid includes: 1. A process for the preparation of lactic acid comprising:a) providing an aqueous medium comprising magnesium lactate;b) adding to the aqueous medium comprising magnesium lactate a monovalent base to form an aqueous medium comprising a water soluble monovalent lactate salt and a solid magnesium base;c) separating the magnesium base from the aqueous medium comprising the water soluble monovalent lactate salt;d) adjusting the concentration of the monovalent lactate salt in the aqueous medium to a value between 10 and 30 wt. %,e) subjecting the aqueous medium comprising the monovalent lactate salt to water-splitting electrodialysis, to produce a first solution comprising monovalent base and a second solution comprising lactic acid and monovalent lactate salt, the electrodialysis being carried out to a partial conversion of 40 to 98 mole %;f) separating the second solution comprising lactic acid and monovalent lactate salt into lactic acid and a solution comprising the monovalent lactate salt by vapour-liquid separation;g) recycling the solution of step f) comprising the monovalent lactate salt to step d).2. The process according to claim 1 , wherein the vapour-liquid separation comprises distillation.3. The process according to claim 1 , wherein the electrodialysis is carried out to a partial conversion of 40 to 95 mole %.4. The process according to claim 3 , wherein the electrodialysis is carried out to a partial conversion of about 85 mole %.5. The process according to claim 1 , wherein concentration of the monovalent lactate salt in the aqueous medium of d) is adjusted to a value between 20 and 25 wt. %.6. The process according to claim 1 , wherein the first solution comprising the monovalent base produced by the water-splitting electrodialysis of step e) is recycled to step b).7. The process according to claim 1 , wherein the water-splitting electrodialysis is carried out in an electrodialysis apparatus ...

Подробнее
05-09-2013 дата публикации

Fluorinated monomer of cyclic acetal structure, polymer, resist protective coating composition, resist composition, and patterning process

Номер: US20130231491A1
Принадлежит: Shin Etsu Chemical Co Ltd

A fluorinated monomer of cyclic acetal structure has formula (1) wherein R is a C 1 -C 20 alkyl group which may be substituted with halogen or separated by oxygen or carbonyl, and Z is a divalent organic group which forms a ring with alkylenoxy and contains a polymerizable unsaturated group. A polymer derived from the fluorinated monomer may be endowed with appropriate water repellency, water sliding property, lipophilicity, acid lability and hydrolyzability and is useful in formulating a protective coating composition and a resist composition.

Подробнее
12-09-2013 дата публикации

Condensation and washing device, polymerisation device and method for cleaning process steam during the production of polylactide

Номер: US20130236366A1
Принадлежит: Uhde Inventa Fischer GmbH

The present invention relates to a condensation and washing device with which in particular the process vapours which occur during the production of polylactide can be processed and cleaned. Furthermore, the present invention relates to a polymerisation device for the production of polylactide and also to a method for processing process vapours which occur during the production of polylactide; possibilities for use of both the condensation and washing devices and of the method are likewise mentioned.

Подробнее
12-09-2013 дата публикации

METHOD OF PREPARING CYCLIC CARBONATES, CYCLIC CARBAMATES, CYCLIC UREAS, CYCLIC THIOCARBONATES, CYCLIC THIOCARBAMATES, AND CYCLIC DITHIOCARBONATES

Номер: US20130237701A1

A method of preparing a cyclic monomer, comprising: forming a first mixture comprising a precursor compound, bis(pentafluorophenyl)carbonate, and a catalyst; wherein the precursor compound has a structure comprising a) two or more carbons, and b) two functional groups selected from the group consisting of primary amine, secondary amine, thiol group, hydroxyl group, and combinations thereof; and agitating the first mixture at a temperature effective to form a second mixture comprising the cyclic monomer, the cyclic monomer selected from the group consisting of a cyclic carbonate, a cyclic carbamate, a cyclic urea, a cyclic thiocarbonate, a cyclic thiocarbamate, and a cyclic dithiocarbonate. 2. The method of claim 1 , wherein the bis(pentafluorophenyl)carbonate reacts only with the two X groups.3. The method of claim 1 , wherein each X group is OH.4. The method of claim 1 , wherein one X group is OH claim 1 , and another X group is NH.5. The method of claim 1 , wherein n is 1.6. The method of claim 1 , wherein the cyclic monomer is a cyclic carbonate.7. The method of claim 1 , wherein the cyclic monomer is a cyclic carbamate.8. The method of claim 1 , wherein the cyclic monomer is a cyclic urea.9. The method of claim 1 , wherein the cyclic monomer is a cyclic thiocarbonate.10. The method of claim 1 , wherein the cyclic monomer is a cyclic thiocarbamate.11. The method of claim 1 , wherein the cyclic monomer is a cyclic dithiocarbonate.12. The method of claim 1 , wherein the catalyst is cesium fluoride.14. The method of claim 13 , wherein each Y is O.15. The method of claim 13 , wherein one Y is O claim 13 , and another Y is NH.16. The method of claim 13 , wherein n is 1.18. The method of claim 17 , wherein each X is OH.19. The method of claim 17 , wherein one X is OH claim 17 , and another X is NH.20. The method of claim 17 , wherein the cyclic monomer is a cyclic carbonate.21. The method of claim 17 , wherein the cyclic monomer is a cyclic carbamate.22. The method of ...

Подробнее
19-09-2013 дата публикации

Prodrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae

Номер: US20130245284A1
Принадлежит:

Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition. 2. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.3. The compound of wherein Ris selected from mono- and polyfluoro-substituted arylalkyl moieties.4. The compound of wherein Ris selected from mono- and difluoro-substituted benzyl moieties.5. The compound of in at least one of human plasma and contact with an enzyme in a streptococcal mevalonate biosynthetic pathway.7. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.8. The compound of wherein Ris selected from aryl claim 7 , mono- and polyfluoroaryl claim 7 , arylalkyl claim 7 , mono- and polyfluoroarylalkyl moieties.9. The compound of wherein Ris selected from phenyl claim 8 , mono- and polyfluorophenyl claim 8 , benzyl claim 8 , monofluorobenzyl and polyfluorobenzyl moieties.11. The compound of wherein X is selected from NH and O; and Ris independently selected from fluoromethyl and trifluoromethyl moieties.12. The compound of where Ris selected from arylalkyl claim 11 , mono- and polyfluoro-substituted arylalkyl moieties.13. The compound of wherein Rand Rare independently selected from H and alkyl moieties.14. The compound of wherein at least one of Rand Ris methyl.16. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.17. The compound of wherein Ris selected from alkyl claim 16 , mono- and polyfluoro-substituted alkyl claim 16 , aryl claim 16 , mono- and polyfluoro-substituted aryl claim 16 , arylalkyl claim 16 , mono- and polyfluoro-substituted arylalkyl moieties.18. The compound of wherein X is O; Ris selected from alkyl claim 15 , aryl and arylalkyl moieties; and Rand Rare independently selected from H and acetyl moieties.19. The compound of wherein at least one of Rand Ris acetyl.21. The compound of ...

Подробнее
26-09-2013 дата публикации

Prodrugs of Substituted 1,3-Dioxanes and Their Uses

Номер: US20130253045A1
Принадлежит: EVOLVA SA

The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. 29-. (canceled)1115-. (canceled)16. A method for treating or preventing a disorder associated with a thromboxane A2 or peroxisome proliferator-activated receptors claim 1 , the method comprising: administering to a subject an effective amount of a compound of or acceptable salts claim 1 , N-oxides claim 1 , hydrates claim 1 , or solvates thereof; and pharmaceutically-acceptable carrier or diluent.17. The method of claim 16 , wherein the disorder is selected from the group consisting of diabetes claim 16 , cancer claim 16 , inflammation claim 16 , AIDS claim 16 , metabolic syndrome claim 16 , obesity claim 16 , pre-diabetes claim 16 , hypertension and dyslipidemia.18. The method of claim 17 , wherein the subject is a human.1923-. (canceled)24. The method of claim 16 , wherein the disorder is selected from the group consisting of myocardial infarction claim 16 , thrombosis claim 16 , thrombotic disorders claim 16 , pulmonary hypertension claim 16 , atherosclerosis claim 16 , diabetic nephropathy claim 16 , retinopathy claim 16 , peripheral arterial disease claim 16 , lower limb circulation claim 16 , pulmonary embolism claim 16 , thrombus formation claim 16 , stent-triggered thrombus formation claim 16 , stent-triggered hyperplasia claim 16 , septic shock claim 16 , preeclampsia claim 16 , asthma claim 16 , allergic rhinitis claim 16 , tumour angiogenesis and metastasis.25. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.26. (canceled)27. The composition according to claim 25 , wherein the ...

Подробнее
03-10-2013 дата публикации

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses

Номер: US20130261087A1
Принадлежит: Siga Technologies Inc

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Подробнее
03-10-2013 дата публикации

NEPRILYSIN INHIBITORS

Номер: US20130261316A1
Принадлежит: THERAVANCE, INC.

In one aspect, the invention relates to compounds having the formula: 14-. (canceled)5. The compound of claim 25 , where Ris selected from —ORand —NRR; Ris H; Ris H or —OH; and Ris H.8. The compound of claim 25 , where Ris —CHOH and Ris H.9. The compound of claim 25 , where Ris selected from —CHOH claim 25 , —CHOP(O)(OH) claim 25 , and —CHOC(O)CH(R)NH; Ris —CH; and Ris —CH(CH).10. The compound of claim 25 , where Ris taken together with Rto form —CHO—CRR—; Rand Rare independently selected from H and —Calkyl; and Ris —CH.11. The compound of claim 25 , where Z is —CH—.12. The compound of claim 25 , where Z is —N—.1318-. (canceled)19. The compound of claim 25 , where a is 0.20. The compound of claim 25 , where b is 0 or b is 1 and Ris halo.21. The compound of claim 25 , where the methylene linker on the biphenyl is substituted with two —CHgroups.23. The compound of claim 25 , where a is 0; b is 0 or b is 1 and Ris halo; and the methylene linker on the biphenyl is optionally substituted with two —CHgroups.24. (canceled)2631-. (canceled) This application claims the benefit of U.S. Provisional Application No. 61/443,827, filed on Feb. 17, 2011; the entire disclosure of which is incorporated herein by reference.1. Field of the InventionThe present invention relates to novel compounds having neprilysin-inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat diseases such as hypertension, heart failure, pulmonary hypertension, and renal disease.2. State of the ArtNeprilysin (neutral endopeptidase, EC 3.4.24.11) (NEP), is an endothelial membrane bound Zn metallopeptidase found in many organs and tissues, including the brain, kidneys, lungs, gastrointestinal tract, heart, and the peripheral vasculature. NEP degrades and inactivates a number of endogenous peptides, such as enkephalins, circulating bradykinin, angiotensin ...

Подробнее
10-10-2013 дата публикации

TREATMENT OF MITOCHONDRIAL DISEASES

Номер: US20130267538A1
Принадлежит:

The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein. 2. The method of claim 1 , comprising administering to said subject a therapeutically effective amount of a compound of Formula I.3. The method of claim 2 , comprising administering the compound of Formula I wherein Ris hydrogen claim 2 , Calkyl claim 2 , or Calkenyl.4. The method of claim 2 , comprising administering the compound of Formula I wherein Rand Rare independently of each other Calkyl or halogen.5. The method of claim 4 , comprising administering the compound of Formula I wherein Ris Calkyl and Ris Calkyl.6. The method of claim 2 , comprising administering the compound of Formula I wherein Ris Calkyl claim 2 , and Ris Calkyl or Calkenyl.7. The method of claim 2 , comprising administering the compound of Formula I wherein Rand Rtaken together with the carbon to which they are attached form a 5-6 membered carbocyclic ring claim 2 , optionally substituted with Calkyl claim 2 , Calkoxy claim 2 , hydroxy claim 2 , carboxy claim 2 , carboxyalkyl claim 2 , alkoxycarbonyl claim 2 , alkoxycarbonylalkyl claim 2 , aminocarbonyl claim 2 , aminocarbonylalkyl claim 2 , or hydroxyalkyl.8. The method of claim 1 , comprising administering to said subject a therapeutically effective amount of a compound of Formula II.9. The method of claim 8 , comprising administering the compound of Formula II claim 8 , wherein Ris —COOH claim 8 , or —COORand Ris Calkyl.11. The method of claim 1 , comprising administering a therapeutically effective amount ...

Подробнее
10-10-2013 дата публикации

Substituted 1,3-Dioxanes Useful as PPAR Modulators

Номер: US20130267561A1
Принадлежит: EVOLVA SA

Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases. 25-. (canceled)720-. (canceled)21. The compound according to claim 1 , wherein said compound is (Z)-6-((2S claim 1 ,4S claim 1 ,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1 claim 1 ,3-dioxan-5-yl)-hex-4-enoic acid.22. The compound according to claim 1 , wherein said compound is (Z)-6-((2S claim 1 ,4S claim 1 ,5R)-2-(2-chlorophenyl)-4-(2-methoxyphenyl)-1 claim 1 ,3-dioxan-5-yl)-hex-4-enoic acid.23. The compound according to claim 1 , wherein said compound is (Z)-6-((2S claim 1 ,4S claim 1 ,5R)-2-(2-chlorophenyl)-4-(2-acetoxyphenyl)-1 claim 1 ,3-dioxan-5-yl)-hex-4-enoic acid.24. The compound according to claim 1 , wherein said compound is methyl(Z)-6-((2S claim 1 ,4S claim 1 ,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1 claim 1 ,3-dioxan-5-yl)hex-4-enoate.2549-. (canceled)50. A method of treating or preventing a clinical condition associated with TP in an individual in need thereof claim 6 , said method comprising a therapeutically effective amount of a compound of .51. The method according to claim 50 , wherein said clinical condition is selected from the group consisting of myocardial infarction claim 50 , thrombosis claim 50 , thrombotic disorders claim 50 , pulmonary hypertension claim 50 , atherosclerosis claim 50 , diabetic nephropathy claim 50 , retinopathy claim 50 , peripheral arterial disease claim 50 , lower limb circulation claim 50 , pulmonary embolism claim 50 , thrombus formation claim 50 , stent-triggered thrombus formation claim 50 , stent-triggered hyperplasia claim 50 , stent-induced restenosis claim 50 , hyperplasia claim 50 , septic shock claim 50 , preeclampsia claim 50 , asthma claim 50 , rhinitis claim 50 , ...

Подробнее
24-10-2013 дата публикации

2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES

Номер: US20130281486A1
Принадлежит:

Compounds of formula I 135-. (canceled)37. The method according to claim 36 , wherein the disease or the condition is a mental disorder propagated by stress claim 36 , Parkinson's disease claim 36 , depression claim 36 , schizophrenia claim 36 , attention deficit hyperactivity disorder claim 36 , post-traumatic stress disorder claim 36 , obsessive compulsive disorder claim 36 , Tourette's syndrome claim 36 , blepharospasm or other focal dystonias claim 36 , temporal lobe epilepsy with psychosis claim 36 , a drug-induced psychosis claim 36 , Huntington's disease claim 36 , a disorder caused by fluctuation of the levels of sex hormones claim 36 , panic disorder claim 36 , Alzheimer's disease claim 36 , and/or mild cognitive impairment.3839-. (canceled)40. The method according to claim 36 , wherein the disease or condition is depression claim 36 , schizophrenia claim 36 , and/or Alzheimer's disease. The present invention relates to pharmacologically active 3-substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)azacycles, or pharmaceutically acceptable salts and esters thereof, as well as to pharmaceutical compositions comprising them and to their use as alpha2C antagonists.It is generally known and accepted in the art that compounds exhibiting alpha adrenergic activity may be used for the treatment of a wide variety of diseases and conditions of the peripheric system and the central nervous system (CNS).The alpha adrenergic receptors can be divided on a pharmacological basis into alpha1 and alpha2 adrenoceptors, which can both be further divided into subtypes. Three genetically encoded subtypes, namely alpha2A, alpha2B, and alpha2C adrenoceptors, have been discovered in human. A fourth pharmacologically defined subtype, namely alpha2D adrenoceptor, is known in some other mammals and in rodents. It corresponds to the genetically defined alpha2A adrenoceptor.The alpha2 adrenoceptor subtypes have distinct tissue distributions and functional roles. For instance, while ...

Подробнее
21-11-2013 дата публикации

Liquid-crystalline compounds and liquid-crystalline media

Номер: US20130306908A1
Принадлежит: Merck Patent GmBH

The present invention relates to liquid-crystalline compounds containing an O-heterocyclic ring, three partially fluorinated benzene rings and a —CF 2 O— bridge between the rings. In addition, the invention relates to liquid-crystalline media prepared therewith and to liquid-crystal display devices (LC displays) containing these media.

Подробнее
21-11-2013 дата публикации

Ketal compounds and uses thereof

Номер: US20130310288A1
Принадлежит: Segetis Inc

Various esterified alkyl ketal ester or hydroxyalkyl ketal ester products are useful as components of organic polymer compositions. The ketal esters are produced in certain transesterifications between alkyl ketal esters and/or hydroxyalkyl ketal esters and polyols, aminoalcohols, polyamines, and/or polycarboxylic acids. The products are excellent plasticizers for a variety of organic polymers, notable poly(vinyl chloride) plastisols. The products are also very good lubricants for many lubrication applications.

Подробнее
05-12-2013 дата публикации

Process for preparing styrene derivatives

Номер: US20130324745A1
Принадлежит: Saltigo GmbH

A process is provided which allows the synthesis of a large number of styrene derivatives with formation of C—C bonds, with use being possible of economically advantageous substrates, readily available carbon nucleophiles, and both inexpensive and environmentally unproblematic catalyst systems, permitting reaction under mild conditions and a high compatibility with functional groups on the reactants involved.

Подробнее
12-12-2013 дата публикации

PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

Номер: US20130331396A1
Принадлежит: Janssen Pharmaceutica NV

Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). 126.-. (canceled)28. A method according to claim 27 , wherein said compound is selected from the group consisting of:4-naphthalen-2-ylmethyl-piperazine-1-carboxylic acid phenylamide;4-quinolin-2-ylmethyl-piperazine-1-carboxylic acid phenylamide;4-benzo[b]thiophen-2-ylmethyl-piperazine-1-carboxylic acid phenylamide;4-(3,4-dibromo-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(1-methyl-1H-indol-2-ylmethyl)-piperazine-1-carboxylic acid phenylamide;4-quinolin-3-ylmethyl-piperazine-1-carboxylic acid phenylamide;4-(4-iodo-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(3-benzyloxy-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(5-bromo-2-hydroxy-3-methoxy-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(4-bromo-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(3-phenoxy-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(3-bromo-4-fluoro-benzyl)piperazine-1-carboxylic acid phenylamide;4-indan-5-ylmethyl-piperazine-1-carboxylic acid phenylamide;4-benzo[b]thiophen-3-ylmethyl-piperazine-1-carboxylic acid phenylamide;4-(4-isopropyl-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(4-ethyl-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(5-bromo-2-hydroxy-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-piperazine-1-carboxylic acid phenylamide;4-(4-methoxy-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(3-vinyl-benzyl)-piperazine-1-carboxylic acid phenylamide;4-(2,3-dihydro-benzofuran-5-ylmethyl)-piperazine-1-carboxylic acid phenylamide;4-(3-methoxy-benzyl)-piperazine-1- ...

Подробнее
19-12-2013 дата публикации

Heteroarylcarboxylic acid ester derivative

Номер: US20130338132A1
Принадлежит: Ajinomoto Co Inc

Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Подробнее
19-12-2013 дата публикации

HIV-1 INHIBITING PHARMACEUTICAL COMPOSITION CONTAINING AN ECKLONIA CAVA-DERIVED PHLOROGLUCINOL POLYMER COMPOUND

Номер: US20130338218A1

The present invention relates to a HIV-1 inhibiting pharmaceutical composition containing, as an active ingredient, 6,6′-bieckol which is a phloroglucinol polymer compound separated from Ecklonia cava. The Ecklonia cava-derived 6,6′-bieckol according to the present invention inhibits HIV-1 induced cell fusion, the cell lysis effect, and the cytopathogenic effect including virus p24 antibody production, exhibits RT enzyme inhibition activity and HIV-1 infection inhibition activity, and shows no cytotoxicity at the concentration that almost perfectly inhibits HIC-1 replication. 1. A method of treating an HIV-1 infected patient comprising:administering a pharmaceutical composition comprising a phloroglucinol polymer compound derived from Ecklonia cava as an active ingredient at a dose determined to be non-cytoxic and inhibit HIV-1 replication and reverse transcriptase activity in a patient.2. The method of claim 1 , wherein the phloroglucinol polymer compound is 6 claim 1 ,6′-bieckol. This application is a divisional of U.S. patent application Ser. No. 13/123,206, filed Jul. 1, 2011, which is a national stage application under 35 USC 371 of International Application No. PCT/KR2009/005354, filed Sep. 21, 2009, which claims the priority of Korean Patent Application No. 10-2008-0098327, filed Oct. 7, 2008, the contents of all of which prior applications are incorporated herein by reference.The present invention relates to a HIV-1 inhibiting pharmaceutical composition containing an Ecklonia cava-derived phloroglucinol polymer compound. More particularly, the present invention relates to a HIV-1 inhibiting pharmaceutical composition containing 6,6′-bieckol as an active ingredient which is a phloroglucinol polymer compound separated from Ecklonia cava.Human immunodeficiency virus type-1 (Human Immunodeficiency virus type-1; HIV-1) is identified as the causative agent of acquired immunodeficiency syndrome (AIDS) which is one of the most important diseases with about 33 ...

Подробнее
26-12-2013 дата публикации

BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION

Номер: US20130345195A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of formula (I): 120-. (canceled)21. A compound selected from the group consisting of:1-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]pyrrolidine;4-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]morpholine;1-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]-4,4-dimethylpiperidine;8-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]-2,8-diazaspiro[4.5]decan-1-one;1-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]-4-fluoropiperidine;(1s,4s)-7-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]-7-azabicyclo[2.2.1]heptane;4-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]thiomorpholine 1,1-dioxide;1-{4-[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]benzyl}-N,N-dimethylpiperidine-4-carboxamide;(3S)-1-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]pyrrolidin-3-ol;1-({1-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]piperidin-3-yl}methyl)pyrrolidin-2-one;1-{4-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]piperazin-1-yl}ethanone;2-{[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]amino}-1-(pyrrolidin-1-yl)ethanone;N-{4-[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]benzyl}-N-methyl-1-(methylsulfonyl)piperidin-4-amine;1-{4-[{4-[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]benzyl}(methyl)amino]piperidin-1-yl}ethanone;3-[4-(pyrrolidin-1-ylmethyl)phenyl]-2,3-dihydro[1,4]dioxino[2,3-b]pyridine;7-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine;3-{4-[(1,1-dioxidothiomorpholin-4-yl)methyl]phenyl}-2,3-dihydro[1,4]dioxino[2,3-b]pyridine;3-[4-(morpholin-4-ylmethyl)phenyl]-2,3-dihydro[1,4]dioxino[2,3-b]pyridine;(3R)-1-{4-[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]benzyl}piperidine-3-carboxylic acid;(3S)-1-{4-[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]benzyl}piperidine-3-carboxylic acid;1-(1-{4-[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]benzyl}piperidin-4-yl)-2,2,2-trifluoroethanol;2-(1-{4-[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]benzyl}piperidin-4-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol;N-[4-(2,3-dihydro-1,4-benzodioxin-2-yl)benzyl]-2-methylpropan-2-amine;(2R)—N-[4-(2,3-dihydro-1, ...

Подробнее
02-01-2014 дата публикации

B- and y -diketones and y -hydroxyketones as wnt/ b -catenin signaling pathway activators

Номер: US20140005228A1
Принадлежит: Samumed LLC

The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

Подробнее
23-01-2014 дата публикации

PROCESS FOR MAKING CHEMICAL DERIVATIVES

Номер: US20140024769A1
Принадлежит: METABOLIX, INC.

Process and methods for making glycolic acid chemical intermediates and derivatives from biomass are described herein. 1. A method of producing a glycolic acid monomer component product from a genetically modified polyhydroxyalkanoate (PHA) biomass , comprising:heating the biomass to release a glycolic acid monomer component from the PHA, optionally in the presence of a catalyst, wherein the glycolic acid monomer component yield is about 70% based on one gram of glycolic acid monomer component product per gram of polyhydroxyalkanoate.2. The method of claim 1 , further including producing a glycolide component.3. The method of claim 1 , wherein the biomass is dried prior to heating.4. The method of claim 1 , wherein the biomass is from a recombinant host selected from a plant crop claim 1 , bacteria claim 1 , a yeast claim 1 , a fungi claim 1 , an algae claim 1 , a cyanobacteria claim 1 , or a mixture of any two or more thereof.5. The method of claim 4 , wherein the host is bacteria.6Escherichia coli, Alcaligenes eutrophusRalstonia eutrophaBacillusAlcaligenes latus, Azotobacter, Aeromonas, Comamonas, Pseudomonads, Pseudomonas, Ralstonia, KlebsiellaSynechococcusSynechococcusSynechocystis, Thermosynechococcus elongatusChlorobium tepidum Chloroflexusauranticus, Chromatium tepidum, Chromatium vinosum Rhodospirillum rubrum, Rhodobacter capsulatusRhodopseudomonas palustris.. The method of claim 5 , wherein the bacteria is selected from (renamed as ) claim 5 , spp. claim 5 , ) claim 5 , sp PCC7002 claim 5 , sp. PCC 7942 claim 5 , sp. PCC 6803BP-I claim 5 , claim 5 , and7. The method of claim 4 , wherein the host is a plant crop.8. The method of claim 7 , wherein the plant crop is selected from tobacco claim 7 , sugarcane claim 7 , corn claim 7 , switchgrass claim 7 , miscanthus sorghum claim 7 , sweet sorghum claim 7 , or a mixture of any two or more thereof.9. The method of claim 1 , wherein the polyhydroxyalkanoate is a polyglycolic acid or a co-polymer thereof.10. The ...

Подробнее
23-01-2014 дата публикации

PREPARATION OF 3,5-DIOXO HEXANOATE ESTER IN TWO STEPS

Номер: US20140024842A1
Принадлежит: LONZA LTD

The invention discloses a method for the preparation of tert-butyl 6-chloro-3,5-dioxohexanoate from Meldrum's acid derivative and its use for the preparation of tert-butyl(4R,65)-(6-hydroxymethyl-2,2-dimethyl-1,3-dioxan-4-yl)acetate (BHA), Rosuvastatin and Atorvastatin. 120-. (canceled)22. Method (B) according to claim 21 , wherein R1-IV and R3 are identical and are Cl or Br.23. Method (B) according to claim 21 , wherein base (B) is selected from the group consisting of N(R4)(R5)R6 claim 21 , 1 claim 21 ,4-diazabicyclo[2.2.2]octane claim 21 , a hexamethyldisilazide claim 21 , a Calkoxide salt of claim 21 , a Ccarboxylate salt of claim 21 , a carbonate salt of claim 21 , a hydrogen carbonate salt of claim 21 , a phosphate salt of claim 21 , a monohydrogenphosphate salt of or a dihydrogenphosphate salt of Na claim 21 , of K or of Li claim 21 , 1 claim 21 ,8-diazabicyclo[5.4.0]undec-7-ene claim 21 , NaNH claim 21 , KNH claim 21 , NaH claim 21 , KH claim 21 , CaH claim 21 , pyridine claim 21 , pyridine substituted with 1 or 2 independently selected identical or different Calkyl residues claim 21 , N claim 21 ,N-dimethyl-4-pyridinamine claim 21 , morpholine claim 21 , 4-methylmorpholine claim 21 , 1-methylpiperidine claim 21 , imidazol claim 21 , benzimidazol claim 21 , 2-methylimidazole claim 21 , 4-methylimidazole claim 21 , 2-ethylimidazole claim 21 , 2-ethyl-4-methylimidazole claim 21 , 2-isopropylimidazole claim 21 , 2-phenylimidazole claim 21 , 4-phenylimidazole claim 21 , picoline claim 21 , CsCO claim 21 , NaOH claim 21 , KOH claim 21 , Ca(OH)and mixtures thereof; with R4 claim 21 , R5 and R6 as defined in .24. Method (B) according to claim 21 , wherein R4 claim 21 , R5 claim 21 , R6 are identical or different and independently from each other selected from the group consisting of cyclohexyl claim 21 , phenyl claim 21 , methyl claim 21 , ethyl claim 21 , n-propyl claim 21 , iso-propyl claim 21 , n-butyl claim 21 , iso-butyl claim 21 , sec-butyl claim 21 , tert- ...

Подробнее
30-01-2014 дата публикации

RECOVERY OF LACTIC ACID VALUES FROM A MESO-LACTIDE STREAM

Номер: US20140031566A1
Принадлежит: NATUREWORKS LLC

Lactic acid equivalents are recovered from a starting lactide stream by catalytically racemizing a portion of the lactide in the stream at a temperature of 180° C. or below. This increases the proportion of two species of lactide (i.e., at least two of S,S-, R,R- or meso-lactide) at the expense of the third species. The racemized mixture so obtained can be separated to recover some or all of one or more of the lactide species from the remaining lactide species, by a process such as melt crystallization or distillation. Impurities in the starting lactide stream usually are retained mostly in the remaining meso-lactide, so a highly purified S,S- and/or R,R-lactide stream can be produced in this manner. Such a purified S,S- and R,R-lactide stream is suitable for polymerization to form a polylactide. 1. A process for recovering lactic acid values from a starting lactide composition , comprisinga) subjecting a starting lactide composition to a temperature of up to 170° C. in the presence of a racemization catalyst for a time sufficient to racemize at least a portion of the lactide in the starting lactide composition to form a racemized lactide mixture that contains meso-lactide, S,S-lactide and R,R-lactide in relative proportions different than in the starting lactide composition.3. The process of claim 2 , wherein the racemization catalyst is 1 claim 2 ,4-dimethyl piperazine or 1 claim 2 ,4-diethyl piperazine.5. The process of claim 4 , wherein X is an —NR′R″ group claim 4 , wherein R′ and R″ are each alkyl or aryl-substituted alkyl claim 4 , or R′ and R″ together form a divalent group that forms a ring structure that includes the nitrogen atom of the —NR′R″ group.6. The process of claim 4 , wherein the racemization catalyst is 4-dimethylaminopyridine or 4-diethylaminopyridine.7. The process of claim 1 , wherein the racemization catalyst is an alkali metal salts of an alkanoic acid having one to 6 carbon atoms.8. The process of claim 7 , wherein the racemization ...

Подробнее
06-02-2014 дата публикации

PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS

Номер: US20140038951A1
Принадлежит: Omeros Corporation

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same. 1. (canceled)3. The method of wherein the neurological disorder is selected from the group consisting of psychotic disorders claim 2 , anxiety disorders claim 2 , movement disorders and/or neurological disorders such as Parkinson's disease claim 2 , Huntington's disease claim 2 , Alzheimer's disease claim 2 , encephalitis claim 2 , phobias claim 2 , epilepsy claim 2 , aphasia claim 2 , Bell's palsy claim 2 , cerebral palsy claim 2 , sleep disorders claim 2 , pain claim 2 , Tourette's syndrome claim 2 , schizophrenia claim 2 , delusional disorders claim 2 , bipolar disorders claim 2 , post-traumatic stress disorders claim 2 , drug-induced psychosis claim 2 , panic disorders claim 2 , obsessive-compulsive disorders claim 2 , attention-deficit disorders claim 2 , disruptive behavior disorders claim 2 , autism claim 2 , depression claim 2 , dementia claim 2 , cognitive disorders claim 2 , epilepsy claim 2 , insomnias and multiple sclerosis.4. The method of wherein the neurological disorder is schizophrenia.5. The method of wherein the neurological disorder is post-traumatic stress disorder.7. The method of wherein Rand Rare the same or different and ...

Подробнее
13-02-2014 дата публикации

Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex

Номер: US20140045903A1
Принадлежит: Intrexon Corporation

The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. 114-. (canceled)15. A compound selected from the group consisting of:5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethoxy-4-methyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethyl-benzoyl)-hydrazide;5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide;5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethoxy-4-methyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethyl-benzoyl)-hydrazide;5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide;3,5-dimethoxy-4-methyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5-dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5- ...

Подробнее
20-02-2014 дата публикации

CONTINUOUS PROCESS FOR THE PRODUCTION OF BETA-KETO ESTERS BY CLAISEN CONDENSATION

Номер: US20140051869A1
Принадлежит: Phoenix Chemicals Limited

A continuous process for producing compounds having the general formula (6) is provided: 2. A process according to wherein the stoichiometric ratio of alkali metal or alkaline earth metal amide base claim 1 , alkyl lithium or a Grignard reagent to compound (5) supplied to the and/or to the separate reaction zone is less than about 4.5:1.3. A process according to wherein the steps of providing to the reaction zone a continuous stream of a compound of formula (3) and a continuous stream of an alkali metal or alkaline earth metal amide base claim 1 , alkyl lithium or Grignard reagent claim 1 , and the steps of providing to the or the separate reaction zone a continuous stream of a compound of formula (5) are sequential steps.4. A process according to wherein the temperature at which compounds (4) and (5) are reacted together is above 25° C.5. A process according to wherein the temperature at which compounds (4) and (5) are reacted together is above 30° C.6. A process according to wherein the residence time of the contacted continuous streams of compounds (4) and (5) in the or the separate reaction zone is less than about 5 minutes.7. A process according to wherein the residence time of the contacted continuous streams of compounds (4) and (5) in the or the separate reaction zone is less than about 1 minute.8. A process according to wherein the residence time of the contacted continuous streams of compounds (4) and (5) in the or the separate reaction zone is less than about 50 seconds.9. A process according to wherein the residence time of the contacted continuous streams of compounds (4) and (5) in the or the separate reaction zone is less than about 40 seconds.10. A process according to wherein the residence time of the contacted continuous streams of compound (3) and the alkali metal or alkaline earth metal amide base claim 1 , alkyl lithium or Grignard reagent in the reaction zone is less than about 5 minutes.11. A process according to wherein the enolate compound ...

Подробнее
27-02-2014 дата публикации

MONOMERS AND POLYMERS FOR FUNCTIONAL POLYCARBONATES AND POLY(ESTER-CARBONATES) AND PEG-CO-POLYCARBONATE HYDROGELS

Номер: US20140058058A1
Автор: Song Jie, Xu Jianwen

The invention generally relates to functional polymers and hydrogels. More particularly, the invention provides versatile monomers and polymers with well-defined functionalities, e.g., polycarbonates and poly(ester-carbonates), compositions thereof, and methods for making and using the same. The invention also provides cytocompatible poly(ethylene glycol)-co-polycarobonate hydrogels (e.g., crosslinked by copper-free, strain-promoted “click” chemistry). 3. The compound of claim 2 , wherein Lis a bivalent linear or branched claim 2 , unsubstituted or substituted alkylene group claim 2 , wherein one or more of the carbon atoms may be optionally substituted with a hetero-atom selected from O claim 2 , S and N or with a —(C═O)— group.413-. (canceled)14. The compound of claim 3 , wherein Ris:{'br': None, 'sub': N', 'y', '9, '\ue8a0L-R—R.'}15. (canceled)16. (canceled)18. The compound of claim 17 , wherein Q is a C-Ccyclic group claim 17 , optionally with one or more of the carbon atoms may be optionally substituted with a hetero-atom selected from O claim 17 , S and N or with a —(C═O)— group.22. The monomer unit of claim 21 , wherein Lis a bivalent linear or branched claim 21 , unsubstituted or substituted alkylene group claim 21 , wherein one or more of the carbon atoms may be optionally substituted with a hetero-atom selected from O claim 21 , S and N or with a —(C═O)— group.23. (canceled)24. (canceled)2732-. (canceled)35. (canceled)37. (canceled)38. (canceled)4043-. (canceled)4653-. (canceled)5557-. (canceled)59125-. (canceled) This application is the national phase of PCT/US12/26427, filed on Feb. 24, 2012, which claims the benefit of priority from U.S. Provisional Application Ser. No. 61/446,997, filed on Feb. 25, 2011, and U.S. Provisional Application Ser. No. 61/484,138, filed on May 9, 2011, the entire content of which is incorporated herein by reference in its entirety.The United States Government has certain rights to the invention pursuant to Grant No. ...

Подробнее
13-03-2014 дата публикации

AROMATIC AMIDES AS POTENTIATORS OF BIOEFFICACY OF ANTI-INFECTIVE DRUGS

Номер: US20140073595A1

The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination of the present invention is useful in the treatment of certain infections and disease at lower concentration of anti-infectives necessary to inhibit the growth of microbial strains and may also find applications in reducing the resistance in microorganisms. 132-. (canceled)37. The method of claim 33 , wherein the potentiating compound is in the form of a pharmaceutically acceptable salt selected from hydrochloride claim 33 , acetate claim 33 , succinate claim 33 , and maleate.38. The method of wherein NRRtogether (R+R) represent an amino acid radical comprising at least one of alaninyl claim 33 , leucinyl claim 33 , phenylalaninyl claim 33 , tyrosinyl claim 33 , glycylglycinyl claim 33 , alanylalaninyl or prolinyl; or a heterocyclic amine radical comprising at least one of piperidinyl claim 33 , pyrrolidinyl claim 33 , morpholinyl claim 33 , piperazinyl claim 33 , N-methylpiperazinyl claim 33 , pyrrolyl claim 33 , imidazolyl claim 33 , or oxazolyl.39. The method of claim 33 , wherein the bacterial cell comprises a gram positive bacterium.40Staphylococcus speciesBacillus. The method of wherein the gram positive bacterium comprises at least one of and species.41. The method as claimed in claim 33 , wherein the bacterial cell comprises a gram negative bacterium.42Pseudomonas species, E. coliSalmonella. The method of wherein the gram negative bacterium comprises at least one of and species.43mycobacterium. The method of claim 33 , wherein the bacterial cell comprises species.44. The method of claim 33 , wherein the composition further comprises an effective amount of an anti- ...

Подробнее
13-03-2014 дата публикации

Spirocyclic nitriles as protease inhibitors

Номер: US20140073662A1
Принадлежит: SANOFI

The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments. 2. A pharmaceutical composition comprising a therapeutically effective amount of the compound of or a physiologically tolerated salt thereof and a pharmaceutically acceptable carrier.4. The method of claim 3 , wherein the condition or disorder is osteoarthritis.5. The method of claim 3 , wherein the condition or disorder is bone loss. This application is a continuation of U.S. application Ser. No. 13/248,366, filed Sep. 29, 2011, which is a divisional of U.S. application Ser. No. 12/277,880, filed Nov. 25, 2008, which is a continuation of International Application No. PCT/EP2007/004550, filed May 23, 2007, which are incorporated herein by reference in their entirety; and claims the benefit of priority of German Patent Application No. 102006025630.1, filed Jun. 1, 2006.The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.Proteolytic enzymes, known as proteases and peptidases, are very important enzymes which make up about 2% of the genes in the human organism, pathogenic microorganisms and also other life forms. Their particular significance is that they influence many physiological processes by playing an important role in the activation, synthesis or degradation of other proteins. This inevitably gives rise to a crucial regulatory function starting at conception, birth, growth, maturation, aging, diseases up to death.The balance of the different processes is of crucial significance for the life and survival of the organism. When there is an imbalance of protease-catalyzed processes as a result of endogenous or exogenous factors such as genetic predisposition or environmental factors, massive disruption can occur in the normal ...

Подробнее
20-03-2014 дата публикации

B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS

Номер: US20140080902A1
Принадлежит: Samumed, LLC

The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases. 1. (canceled)4. The method of claim 2 , wherein Ris a substituted or unsubstituted phenyl.12. The method of claim 10 , wherein Ris a substituted or unsubstituted phenyl.19. The method of claim 17 , wherein Ris a substituted or unsubstituted phenyl.27. The method of claim 25 , wherein Ris a substituted or unsubstituted phenyl.32. The method of claim 2 , wherein the compound is topically administered to the mammal.33. The method of claim 10 , wherein the compound is topically administered to the mammal.34. The method of claim 17 , wherein the compound is topically administered to the mammal.35. The method of claim 25 , wherein the compound is topically administered to the mammal. This application is a continuation application of U.S. application Ser. No. 13/211,665, filed Aug. 17, 2011, and claims the benefit of U.S. Provisional Application No. 61/427,974, filed Dec. 29, 2010, and U.S. Provisional Application No. 61/374,687, filed Aug. 18, 2010, each of which is incorporated herein by reference in its entirety.1. Field of the InventionThis invention relates to activators of one or ...

Подробнее
20-03-2014 дата публикации

5-SEC-BUTYL-2-(2,4-DIMETHYL-CYCLOHEX-3-ENYL)-5-METHYL-[1,3]DIOXANE AND PROCESS FOR MAKING THE SAME

Номер: US20140081034A1
Принадлежит: International Flavors & Fragrances Inc.

The present invention is directed to 5-sec-butyl-2-(2,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1,3]dioxane and a novel process for making the same. 1. A process for preparing 5-sec-butyl-2-(2 ,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1 ,3]dioxane consisting essentially of the steps of:(i) reacting 3-methyl-pent-3-en-2-one and hydrogen to provide 3-methyl-pentan-2-one;(ii) reacting 3-methyl-pentan-2-one of step (i) and methyl monochloroacetate to provide 3-sec-butyl-3-methyl-oxirane-2-carboxylic acid methyl ester;(iii) saponifying followed by acidifying and then decarboxylating 3-sec-butyl-3-methyl-oxirane-2-carboxylic acid methyl ester of step (ii) to provide 2,3-dimethyl-pentanal;(iv) reacting 2,3-dimethyl-pentanal of step (iii) and sodium hydroxide to provide 2-sec-butyl-2-methyl-propane-1,3-diol; and(v) reacting 2-sec-butyl-2-methyl-propane-1,3-diol of step (iv) and 2,4-dimethyl-cyclohex-3-enecarbaldehyde to provide 5-sec-butyl-2-(2,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1,3]dioxane.2. The process of claim 1 , wherein step (i) is carried out at a temperature of about 85° C. and a pressure of about 10 bar.3. The process of claim 1 , wherein step (iii) decarboxylating is by refluxing at about 80-90° C.4. A process for preparing 5-sec-butyl-2-(2 claim 1 ,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1 claim 1 ,3]dioxane consisting essentially of the steps of:(i) reacting 3-methyl-pent-3-en-2-one and hydrogen at a temperature of about 85° C. and a pressure of about 10 bar to provide 3-methyl-pentan-2-one;(ii) reacting 3-methyl-pentan-2-one of step (i) and methyl monochloroacetate to provide 3-sec-butyl-3-methyl-oxirane-2-carboxylic acid methyl ester;(iii) saponifying followed by acidifying and then decarboxylating 3-sec-butyl-3-methyl-oxirane-2-carboxylic acid methyl ester of step (ii) to provide 2,3-dimethyl-pentanal, wherein decarboxylating is by refluxing at about 80-90° C.;(iv) reacting 2,3-dimethyl-pentanal of step (iii) and sodium hydroxide to provide 2-sec-butyl-2-methyl- ...

Подробнее
03-04-2014 дата публикации

Novel Ether Linked Compounds and Improved Treatments for Cardiac and Cardiovascular Disease

Номер: US20140094493A1
Принадлежит:

A compound of Formula (I), and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: 2. The compound as claimed in claim 1 , wherein Qand Qor Qand Qtogether form a Cheteroaryl or Cheterocylclic ring; optionally containing one or two heteroatoms selected from N and O claim 1 , optionally substituted by up to two groups selected from R.4. The compound as claimed in claim 1 , wherein Ris chloro claim 1 , bromo or fluoro claim 1 , Calkyl claim 1 , Calkoxy or cyano.5. The compound as claimed in claim 1 , wherein Ris CcycloalkylCalkyl or phenylCalkyl where the Calkyl optionally contains 1 or 2 heteroatoms selected from O.6. The compound as claimed in claim 1 , wherein Rand Rare both hydrogen.7. The compound as claimed in claim 1 , wherein Xis —O—.8. The compound as claimed in claim 1 , wherein Xis phenyl or a 9-10 membered heteroaryl ring.9. The compound as claimed in claim 1 , wherein Xis a 9-10 membered heterocyclic ring selected from isoindoline and 2 claim 1 ,3-dihydroxybenzimidazole10. The compound as claimed in claim 1 , wherein and Ris selected from amino claim 1 , carboxy claim 1 , halo claim 1 , Calkyl claim 1 , Calkoxy claim 1 , Cperfluoroalkyl claim 1 , oxo claim 1 , —NHC(O)Calkyl or —CONH.12. A composition comprising a therapeutically effective amount of a compound of Formula (I) or subformulae or its pharmaceutically acceptable salt and physiologically hydrolysable derivative as defined in in association with one or more pharmaceutical carriers or diluents.13. The compound as claimed in claim 1 , for in the prevention or treatment of a condition selected from ischaemic heart disease claim 1 , hypertension and heart failure claim 1 , more preferably with concomitant respiratory disease claim 1 , in particular asthma or COPD.15. A method for the treatment of a condition selected from ischaemic heart disease claim 1 , hypertension and heart failure claim 1 , more preferably with concomitant ...

Подробнее
10-04-2014 дата публикации

SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4- BENZAMIDE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Номер: US20140100374A1
Принадлежит: LES LABORATOIRES SERVIER

Industrial synthesis process for the compound of formula (I): 2. The process according to claim 1 , wherein the reaction mixture obtained at the end of the reaction of the compound of formula (II) with ammonia is subjected to pyrolysis.3. The process according to claim 2 , wherein the pyrolysis is carried out at a temperature greater than or equal to 200° C.4. The process according to claim 2 , wherein the pyrolysis is carried out at a temperature greater than or equal to 280° C.5. The process according to claim 1 , wherein the conversion of the compound of formula (III) into the compound of formula (IV) is carried out in the presence of hydrogen and a metal or metal-containing catalyst.6. The process according to claim 1 , wherein the compound of formula (V) is 4-(3-chloropropoxy)benzamide.7. The process according to claim 1 , wherein the coupling reaction of the compound of formula (IV) with the compound of formula (V) is carried out in the presence of a carbonate claim 1 , an amine or a hydroxide.8. The process according to claim 1 , wherein the coupling reaction of the compound of formula (IV) with the compound of formula (V) is carried out in the presence of potassium carbonate or triethylamine.9. The process according to claim 1 , wherein the coupling reaction of the compound of formula (IV) with the compound of formula (V) is carried out in a polar medium composed of one or more polar solvents selected from water claim 1 , alcohols claim 1 , ketones claim 1 , ethers claim 1 , amides claim 1 , DMSO and acetonitrile.10. The process according to claim 1 , wherein the coupling reaction of the compound of formula (IV) with the compound of formula (V) is carried out in a water/acetonitrile mixture or a water/isopropanol mixture.11. The process according to claim 1 , wherein the salt formation step in the presence of HCl takes place in a solvent selected from water claim 1 , acetone and an alcohol.12. The process according to claim 1 , wherein the salt formation ...

Подробнее
07-01-2016 дата публикации

METHOD FOR PRODUCING GLYCOLIDE

Номер: US20160002196A1
Принадлежит: KUREHA CORPORATION

A method for producing glycolide (GL) by heating a glycolic acid oligomer (GAO) to depolymerize the GAO. The method for producing GL comprises: a step 1 of heating a mixture containing a GAO having a terminal COOH concentration of 400 eq/t or less and a polar organic solvent to a GAO depolymerization temperature under ambient pressure or reduced pressure; a step 2 of continuing the heating at the temperature for depolymerizing of the GAO and then codistilling out the produced GL and the solvent from the depolymerization reaction system to the outside the reaction system; and a step 3 of obtaining GL from the codistillation product. In the method for producing GL, the GAO is preferably prepared by a GAO production method which comprises a step of condensing glycolic acid (GA) and a dehydration step of continuing the heating together with a polar organic solvent or a depolymerization reaction solution to allow the GA condensation reaction to continue. 1. A method for producing glycolide by heating a glycolic acid oligomer to depolymerize , the method comprising steps below:I. a step 1 of heating a mixture containing a glycolic acid oligomer having a terminal carboxyl group concentration of 400 eq/t or less and a polar organic solvent to a temperature for depolymerizing the glycolic acid oligomer under ambient pressure or reduced pressure;II. a step 2 of continuing the heating at the temperature for depolymerizing the glycolic acid oligomer and then codistilling out, together with the polar organic solvent, glycolide produced by the depolymerization from a depolymerization reaction system containing the mixture; andIII. a step 3 of obtaining glycolide from the codistillation product.2. The method for producing glycolide according to claim 1 , wherein the glycolic acid oligomer is a glycolic acid oligomer having a terminal carboxyl group concentration of 250 eq/t or less.3. The method for producing glycolide according to claim 1 , wherein the glycolic acid oligomer ...

Подробнее
07-01-2016 дата публикации

METHOD FOR PRODUCING GLYCOLIDE

Номер: US20160002197A1
Принадлежит: KUREHA CORPORATION

A method for producing a GL comprising: (I) a heating step of heating a mixture either under normal pressure or reduced pressure at a temperature at which a polyglycolic acid (PGA) undergoes depolymerization, the mixture containing the PGA and a polyethylene glycol ether which is represented by the formula: X—O—(—CHCH—O—)—Y (wherein X and Y are each independently an alkyl group or an aryl group having from 2 to 20 carbon atoms, and p is an integer from 1 to 5) and which has a molecular weight of from 150 to 450 and a boiling point of from 130 to 220° C. at a pressure of 3 kPa; (II) a solution-forming step in which the mixture is rendered in a solution state in which a melt phase of the PGA and a liquid phase consisting of the polyethylene glycol ether essentially form a uniform phase; (III) a GL production step in which a glycolide (GL) is produced by a depolymerization reaction of the PGA by continuing to heat the mixture in the solution state; (IV) a distillation step of distilling off the produced GL together with the polyethylene glycol ether (B) from the depolymerization reaction system; and (V) a recovery step of recovering the GL from the distillate. 1. A method for producing a glycolide by depolymerizing a polyglycolic acid , the method comprising: {'br': None, 'sub': 2', '2', 'p, 'X—O—(—CHCH—O—)—Y\u2003\u2003(1)'}, '(I) a heating step of heating a mixture either under normal pressure or reduced pressure at a temperature at which a polyglycolic acid (A) undergoes depolymerization, the mixture containing the polyglycolic acid (A) and a polyethylene glycol ether (B) which is represented by the following formula (1)(wherein X and Y are each independently an alkyl group or an aryl group having from 2 to 20 carbon atoms, and p is an integer from 1 to 5)and which has a molecular weight of from 150 to 450 and a boiling point of from 130 to 220° C. at a pressure of 3 kPa;(II) a solution-forming step in which the mixture is rendered in a solution state in which a ...

Подробнее
05-01-2017 дата публикации

COMPOUND USEFUL FOR MANUFACTURING SALACINOL, METHOD FOR MANUFACTURING THE COMPOUND, METHOD FOR MANUFACTURING SALACINOL, METHODS FOR PROTECTING AND DEPROTECTING DIOL GROUP, AND PROTECTIVE AGENT FOR DIOL GROUP

Номер: US20170001974A1
Принадлежит: FUJIFILM Corporation

An object of the present invention is to provide a novel compound useful for manufacturing salacinol, a method for manufacturing the compound, a method for manufacturing salacinol, methods for protecting and deprotecting a diol group, and a protective agent for a diol group. A compound represented by Formula (1) is a compound useful for manufacturing salacinol. 2. The compound according to claim 1 ,{'sup': 1a', '1b, 'wherein Rand Rare the same as or different from each other and each represent a carboxy protective group.'}3. The compound according to claim 1 ,{'sup': 2', '3, 'wherein each of Rand Ris a hydroxy group.'}6. The compound according to claim 1 ,{'sup': '5', 'wherein Ris a phenyl group which may be substituted.'}7. The compound according to that is a compound selected from dimethyl 2-((4aS claim 1 ,8aR)-6-phenyltetrahydro[1 claim 1 ,3]dioxino[5 claim 1 ,4-d][1 claim 1 ,3]dioxin-2-yl)malonate claim 1 , dimethyl 2-((4R claim 1 ,5S)-5-hydroxy-4-(hydroxymethyl)-1 claim 1 ,3-dioxan-2-yl)malonate claim 1 , dimethyl 2-((4aR claim 1 ,8aS)-2 claim 1 ,2-dioxidotetrahydro[1 claim 1 ,3]dioxin[5 claim 1 ,4-d][1 claim 1 ,3 claim 1 ,2]dioxathiin-6-yl)malonate claim 1 , (4S claim 1 ,5S)-4-(((2R claim 1 ,3 S claim 1 ,4S)-3 claim 1 ,4-dihydroxy-2-(hydroxymethyl)tetrahydro-1H-thiophen-1-ium-1-yl) methyl-2-(1 claim 1 ,3-dimethoxy-1 claim 1 ,3-dioxopropan-2-yl)-1 claim 1 ,3-dioxan-5-yl sulfate claim 1 , (4S claim 1 ,5 S)-4-(((1 S claim 1 ,2R claim 1 ,3 S claim 1 ,4S)-3 claim 1 ,4-bis(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-1H-thiophen-1-ium-1-yl)methyl)-2-(1 claim 1 ,3-dimethoxy-1 claim 1 ,3-dioxopropan-2-yl)-1 claim 1 ,3-dioxan-5-yl sulfate claim 1 , (4S claim 1 ,5S)-4-(((1 S claim 1 ,2R claim 1 ,3 S claim 1 ,4S)-3 claim 1 ,4-bis((4-methoxybenzyl)oxy)-2-(((4-methoxybenzyl)oxy)methyl)tetrahydro-1H-thiophen-1-ium-1-yl)methyl)-2-(1 claim 1 ,3-dimethoxy-1 claim 1 ,3-dioxopropan-2-yl)-1 claim 1 ,3-dioxan-5-yl sulfate claim 1 , diethyl 2-((4aS claim 1 ,8aR)-6-phenyltetrahydro[1 ...

Подробнее
02-01-2020 дата публикации

METHOD FOR THE ONE-POT PRODUCTION OF ORGANO-IODINATED COMPOUNDS

Номер: US20200002269A1
Принадлежит:

The present invention concerns a process for the preparation of organo-iodized compounds, as well as their preparation intermediates. More particularly, the present invention concerns a process for the preparation of organo-iodized compounds which can be used as preparation intermediates in the synthesis of iodized contrast agents. 19-. (canceled)11. The process of claim 10 , wherein the steps a) and b) are carried out in a single reactor.13. The process of claim 10 , wherein steps a) and b) are carried out in the presence of a solvent selected from the group consisting of dimethylacetamide claim 10 , propylene carbonate claim 10 , acetonitrile claim 10 , tetrahydrofuran claim 10 , and mixtures thereof.14. The process of claim 10 , wherein step b) is carried out in the presence of a chlorination agent selected from the group consisting of thionyl chloride claim 10 , phosphorus oxychloride claim 10 , phosphorus trichloride claim 10 , oxalyl chloride claim 10 , phosphorus pentachloride claim 10 , and methanoyl dichloride. The present invention relates to a process for the preparation of organo-iodized compounds, as well as their preparation intermediates. More precisely, the present invention relates to a process for the preparation of organo-iodized compounds used as preparation intermediates in the synthesis of iodized contrast agents.Currently, the majority of processes for the synthesis of iodized contrast agents use the dichloride of 5-amino-2,4,6-triiodoisophthalic acid (also known as DiCOCl), with the following formula:This compound is used in particular as an intermediate product in the synthesis of many contrast agents such as iopamidol (Iopamiron®), iohexol (Omnipaque®), ioversol (Optiray®), iomeprol (Iomeron®) or iobitridol (Xenetix®).During the synthesis of iodized contrast agents, it is necessary to carry out lengthy steps for separation and purification in order to obtain synthesis intermediates with a good level of purity. These steps considerably ...

Подробнее
07-01-2016 дата публикации

Liquid crystal medium, optical device, and liquid crystal compound

Номер: US20160002536A1
Принадлежит: JNC Corp, JNC Petrochemical Corp

A liquid crystal medium having stability to heat, light and so forth, a wide liquid crystal phase temperature range, a low driving voltage and a small permittivity and exhibiting an optically isotropic liquid crystal phase is described. An optical device or the like having a short response time, a large contrast ratio, a low driving voltage and a small permittivity is also described. The liquid crystal composition contains an achiral component (T) and a chiral agent, and exhibits an optically isotropic liquid crystal phase. The achiral component (T) includes at least one compound represented by formula (1): wherein, for example, R 1 is alkyl having 1 to 12 carbons, A 1 and A 2 are 1,4-phenylene, Z 1 and Z 2 are single bonds, Z 3 is —COO— or —CF 2 O—, L 11 is hydrogen, fluorine or chlorine, Y 1 is fluorine, chlorine, —CF 3 or —OCF 3 , n1 and n2 are each independently 0 or 1, and n1+n2≧1.

Подробнее
07-01-2021 дата публикации

COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES

Номер: US20210002229A1
Принадлежит:

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein Ris -A-Z.3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein Ris —O—X—Y.4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein Ris -A-Z claim 1 , A is a bond claim 1 , and Z is phenyl claim 1 , optionally substituted with one to three R.5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein Xis —CH—.6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein R claim 1 , Rand Rare H claim 1 , and Ris selected from the group consisting of F claim 1 , Cl claim 1 , CH claim 1 , CFand OCH.7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein a ring is formed between one pair of Rand R claim 1 , Rand R claim 1 , Rand R claim 1 , or Rand R.8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein Ris -A-Z claim 1 , and Z is selected from the group consisting of piperidinyl claim 1 , imidazolyl and pyridinyl.9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein n is 0.10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein Ris selected from the group consisting of F claim 1 , Cl claim 1 , CH claim 1 , CFand OCH.11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein the group Ris OCHand Ris F.12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein Rand Rare each H.13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein Rand Rare combined to form a 4- to 8-membered ring or spirocyclic ring claim 1 , optionally having one or two additional ring vertices selected from O claim 1 , N or S; wherein said ring or spirocyclic ring is substituted with 0 to 4 substituents independently selected from the group ...

Подробнее
07-01-2021 дата публикации

GLYCOLIDE PRODUCTION METHOD

Номер: US20210002248A1
Принадлежит: KUREHA CORPORATION

The object of the present invention is to provide a glycolide production method capable of further increasing the production rate of glycolide. The glycolide production method according to the present invention includes adding metal iron to an aqueous glycolic acid solution, subjecting glycolic acid contained in the aqueous glycolic acid solution to which the metal iron is added, to dehydrating polycondensation to obtain a glycolic acid oligomer, and heating and depolymerizing the glycolic acid oligomer to obtain glycolide. 1. A glycolide production method comprising:adding metal iron to an aqueous glycolic acid solution;subjecting glycolic acid contained in the aqueous glycolic acid solution to which the metal iron is added, to dehydrating polycondensation to obtain a glycolic acid oligomer; andheating and depolymerizing the glycolic acid oligomer to obtain glycolide.2. The glycolide production method according to claim 1 , wherein an addition amount of the metal iron is from 10 ppm to 1000 ppm relative to a total mass of the glycolic acid.3. The glycolide production method according to claim 1 , wherein the metal iron is iron powder.4. The glycolide production method according to claim 3 , wherein an average particle size of the iron powder is from 1 μm to 1000 μm.5. The glycolide production method according to claim 1 , wherein a dehydrating polycondensation temperature is from 50° C. to 300° C.6. The glycolide production method according to claim 1 , wherein the depolymerization is carried out in the presence of a polyalkylene glycol ether represented by Formula (1):{'br': None, '[Chemical Formula 1]'}{'br': None, 'i': 'p', 'X—O—(—R—O-)-Y\u2003\u2003(1)'}in Formula (1),R is a methylene group, or a linear or branched alkylene group having from 2 to 8 carbons,X and Y each independently denote an alkyl group or an aryl group having from 2 to 20 carbons,p is an integer from 1 to 5, andwhen p is 2 or greater, a plurality of R moieties may be the same or different. ...

Подробнее
01-01-2015 дата публикации

Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex

Номер: US20150005256A1
Принадлежит:

The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. 15-. (canceled)7. The method of claim 6 , wherein the compound is of the specified formula and:X and X′ are O; [{'sub': 1', '4', '1', '4', '1', '4, '(a) substituted or unsubstituted phenyl wherein the substituents are independently 1-5 H, (C-C)alkyl, (C-C)alkoxy, halo (F, Cl, Br, I), (C-C)haloalkyl, cyano, or nitro; or'}, {'sub': 1', '4', '1', '4', '1', '4, '(b) substituted or unsubstituted 2-pyridyl, 3-pyridyl, or 4-pyridyl, wherein the substituents are independently 1-4 H, (C-C)alkyl, (C-C)alkoxy, halo (F, Cl, Br, I), (C-C)haloalkyl, cyano, or nitro;'}], 'Y is{'sup': '3', 'Ris H, methyl, ethyl, or cyano;'}{'sup': 4', '7', '8, 'sub': 1', '4', '1', '4', '1', '4, 'R, R, and Rare independently: H, (C-C)alkyl, (C-C)alkoxy, halo (F, Cl, Br, I), (C-C)haloalkyl, cyano, or nitro; and'}{'sup': 5', '6, 'sub': 1', '4', '1', '4', '1', '4, 'Rand Rare independently: H, (C-C)alkyl, halo (F, Cl, Br, I), C-Chaloalkyl, (C-C)alkoxy, hydroxy, amino, cyano, or nitro.'}8. (canceled)9. The method of claim 7 , wherein the compound is of the specified formula and: [{'sub': 1', '4', '1', '4', '1', '4, '(a) substituted or unsubstituted phenyl wherein the substituents are independently 1-5 H, (C-C)alkyl, (C-C)alkoxy, halo (F, Cl, Br, I), (C-C)haloalkyl; or'}, {'sub': 1', '4', '1', '4', '1', '4, '(b) substituted or unsubstituted 3-pyridyl, wherein the substituents are independently 1-4 H, (C- ...

Подробнее
13-01-2022 дата публикации

RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT

Номер: US20220011665A1
Автор: NGUYEN KhanhTin
Принадлежит:

A resist composition that contains a base material component exhibiting changed solubility in a developing solution under action of acid and a compound (D0) represented by General Formula (d0), in which R, R, R, and Reach independently represents a hydrogen atom, a hydroxy group, a halogen atom, or an alkyl group; alternatively, Rand R, Rand R, or Rand Rare bonded to each other to form an aromatic ring; Rrepresents a hydrogen atom or an alkyl group; Y represents a group that forms an alicyclic group together with a carbon atom *C; provided that at least one of the carbon atoms that form the alicyclic group is substituted with an ether bond, a thioether bond, a carbonyl group, a sulfinyl group, or a sulfonyl group; m represents an integer of 1 or more, and M represents an m-valent organic cation 2. The resist composition according to claim 1 , wherein a content of the compound (D0) is in a range of 1 to 35 parts by mass with respect to 100 parts by mass of the base material component (A).3. The resist composition according to claim 1 , further comprising an acid generator component (B) generating an acid upon exposure claim 1 , provided that the compound (D0) is excluded from the acid generator component (B).4. The resist composition according to claim 1 , wherein the base material component (A) contains a resin component (A1) claim 1 , and the resin component (A1) has a constitutional unit (a1) that contains an acid-decomposable group having a polarity which is increased by action of an acid.5. A method of forming a resist pattern claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'forming a resist film on a support using the resist composition according to ;'}exposing the resist film; anddeveloping the exposed resist film to form a resist pattern.6. The method of forming a resist pattern according to claim 5 , wherein the resist film is exposed with extreme ultraviolet (EUV) rays or electron beam (EB).8. An acid diffusion-controlling agent ...

Подробнее
12-01-2017 дата публикации

LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME

Номер: US20170008872A1
Автор: BAE Ji Hong, OH Keun Chan
Принадлежит:

A liquid crystal composition including at least one of the liquid crystal molecules represented by Chemical Formulas 1 to 3: 6. The liquid crystal composition of claim 5 , comprisingabout 1 wt % to about 20 wt % of at least one of the liquid crystal molecules represented by Chemical Formula 1-1, Chemical Formula 1-2, Chemical Formula 2-1, Chemical Formula 2-2, Chemical Formula 3-1, and Chemical Formula 3-2, based on the entire weight of the composition.12. The liquid crystal display of claim 11 , comprising:about 1 wt % to about 20 wt % of at least one liquid crystal molecule represented by Chemical Formula 1-1, Chemical Formula 1-2, Chemical Formula 2-1, Chemical Formula 2-2, Chemical Formula 3-1, and Chemical Formula 3-2, based on the entire weight of the liquid crystal layer.13. The liquid crystal display of claim 12 , wherein:the liquid crystal molecules included in the liquid crystal layer are tilted in a direction parallel to branch electrodes when an electric field is not applied to the liquid crystal layer.14. The liquid crystal display of claim 13 , whereinthe liquid crystal molecules are tilted in a direction horizontal to an electric field when the electric field is applied to the liquid crystal layer. This application claims priority to and the benefit of Korean Patent Application No. 10-2015-0098634, filed on Jul. 10, 2015, and all the benefits accruing therefrom under 35 U.S.C. §119, the content of which in its entirety is herein incorporated by reference.(a) Technical FieldThe described technology relates generally to a liquid crystal composition and a liquid crystal display including the same.2. Description of the Related ArtLiquid crystal displays (“LCDs”) are widely used flat panel displays, which include two display panels facing each other, a liquid crystal layer interposed between two display panels, and a field generating electrode such as a pixel electrode and a common electrode positioned on at least one of the two display panels.In an LCD, ...

Подробнее
12-01-2017 дата публикации

Process for Making Chemical Derivatives

Номер: US20170009008A1
Принадлежит:

Process and methods for making glycolic acid chemical intermediates and derivatives from biomass are described herein. 1. A continuous biorefinery process for the production of glycolide from a genetically engineered PHA biomass comprising ,a) culturing the genetically engineered PHA biomass to produce polyglycolide;b) heating the polyglycolide with a catalyst to produce a glycolide monomer component; andc) recovering the glycolide monomer, wherein the biomass is from a recombinant host selected from a plant crop, bacteria, yeast, fungi, algae, cyanobacteria, or a mixture of any two or more thereof.2. The process of claim 1 , wherein the biomass is dried prior to heating.3. The process of claim 1 , wherein the heating is pyrolysis claim 1 , torrefaction or flash pyrolysis.4. The process of claim 1 , wherein the weight percent of catalyst is about 5% to about 15%.5. A method of producing a glycolide component product from a genetically modified polyhydroxyalkanoate (PHA) biomass claim 1 , comprising:heating the biomass optionally in the presence of a catalyst to release a glycolide component from the PHA, wherein the glycolide component yield is about 70% based on one gram of glycolide component per gram of polyhydroxyalkanoate, wherein the biomass is from a recombinant host selected from a plant crop, bacteria, a yeast, a fungi, an algae, a cyanobacteria, or a mixture of any two or more thereof.6. The method of claim 5 , wherein the biomass is dried prior to heating.7. The method of claim 5 , wherein the host is bacteria.8Escherichia coli, Alcaligenes eutrophusRalstonia eutrophaBacillusAlcaligenes latus, Azotobacter, Aeromonas, Comamonas, Pseudomonads, Pseudomonas, Ralstonia, KlebsiellaSynechococcus, SynechococcusSynechocystisThermosynechococcus elongatusChlorobium tepidum Chloroflexusauranticus, Chromatium tepidum, Chromatium vinosum Rhodospirillum rubrum, Rhodobacter capsulatusRhodopseudomonas palustris.. The method of claim 7 , wherein the bacteria is selected ...

Подробнее
14-01-2016 дата публикации

MANUFACTURING METHOD OF LACTIDE FROM LACTIC ACID

Номер: US20160009856A1
Принадлежит:

The present invention provides a method of producing D-type lactide from liquid D-type lactic acid, and a method for producing D-type polylactic acid having a weight average molecular weight of about 50,000˜20,000 g/mol from the produced D-type lactide. The method of the present invention is advantageous in that D-type lactide can be obtained at a high yield by a simple method, compared to the conventional production methods. Consequently, production cost of D-type polylactic acid that is finally obtained from D-type lactide can be reduced. 1. A method of producing D-type lactide , comprising the steps of:(a) converting liquid D-type lactic acid into D-type polylactic acid having a weight average molecular weight of about 600˜1200 g/mol at a temperature of about 130˜150° C. and a pressure of about 10˜200 torr;(b) converting the D-type polylactic acid having a weight average molecular weight of about 600˜1200 g/mol into gas stream by heating D-type polylactic acid in the presence of a zinc oxide catalyst at a temperature of about 230˜240° C. and at a pressure of 200 torr;(c) cooling the gas stream at a temperature of about −78˜10° C. to separate unreacted lactic acid from a mixture; and(d) mixing the mixture with water to separate D-type lactide.2. The method of claim 1 , wherein the zinc oxide catalyst exists in an amount of about 0.01˜1.5% by weight claim 1 , based on D-type polylactic acid.3. The method of claim 1 , wherein a carrier gas is added and the retention time is controlled from about 5˜10 sec in step (b).4. The method of claim 3 , wherein the carrier gas includes a nitrogen gas.5. The method of claim 1 , wherein the mixture and water are mixed at a volume ratio of about 1:0.5˜5 and at a temperature of about 5˜30° C.6. The method of claim 1 , wherein the unreacted lactic acid separated in step (c) is recycled to step (a) to create a continuous cycle.7. A method of producing D-type polylactic acid having a weight average molecular weight of about 50 claim ...

Подробнее
11-01-2018 дата публикации

COMPOUND USEFUL FOR MANUFACTURING SALACINOL, METHOD FOR MANUFACTURING THE COMPOUND, METHOD FOR MANUFACTURING SALACINOL, METHODS FOR PROTECTING AND DEPROTECTING DIOL GROUP, AND PROTECTIVE AGENT FOR DIOL GROUP

Номер: US20180009777A1
Принадлежит: FUJIFILM Corporation

An object of the present invention is to provide a novel compound useful for manufacturing salacinol, a method for manufacturing the compound, a method for manufacturing salacinol, methods for protecting and deprotecting a diol group, and a protective agent for a diol group. A compound represented by Formula (1) is a compound useful for manufacturing salacinol. 2. The manufacturing method according to claim 1 ,{'sup': 1a', '1b', '4a', '4b', '4c, 'wherein each of Rand Ris a carboxy protective group, and each of R, R, and Ris a hydrogen atom.'}4. The manufacturing method according to claim 3 ,{'sup': '5', 'wherein Ris a phenyl group which may be substituted.'}5. The manufacturing method according to claim 3 ,{'sup': 1a', '1b', '4a', '4b', '4c, 'wherein each of Rand Ris a carboxy protective group, and each of R, R, and Ris a hydrogen atom.'} The present application is a Divisional of U.S. application Ser. No. 15/268,829, filed Sep. 19, 2016 which is a continuation of PCT/JP2015/58197 filed on Mar. 19, 2015 and claims priority under 35 U.S.C. § 119 of Japanese Patent Application No. 57961/2014 filed on Mar. 20, 2014, the disclosures of which are incorporated herein by referenceThe present invention relates to a compound useful for manufacturing salacinol and a method for manufacturing the compound. The present invention also relates to a method for manufacturing salacinol, methods for protecting and deprotecting a diol group, and a protective agent for a diol group.In traditional Indian medicine, Salacia reticulata which is a climbing tree of the genus Salacia is used for treating diabetes. Salacinol is a component contained in plants of the genus Salacia such as Salacia reticulata and has a strong α-glucosidase inhibitory activity (Tetrahedron Letters, Vol. 38, No. 48., pp. 8367-8370 (1997)). Salacinol is obtained from, for example, extracts of plants of the genus Salacia (JP3030008B). However, the supply of plants of the genus Salacia is small, and it is difficult to ...

Подробнее
14-01-2021 дата публикации

Synthesis of (2S,3R,4R)-4,5-Dihydroxyisoleucine and Derivatives

Номер: US20210009507A1
Принадлежит:

The invention relates to a method for the preparation of a 4,5-dihydroxyisoleucine derivative comprising the steps of asymmetric Claisen rearrangement of a Z-aminocrotyl-glycin ester and subsequent kinetic resolution of the product diastereomer mix by acylase, and subsequent Sharpless dihydroxylation of the resulting 2-amino-3-methylpent-4-enoic acid derivative. 2. The method of claim 1 , wherein said chiral ligand is selected from ephedrin claim 1 , valinol claim 1 , cinchonidine claim 1 , quinidine and cinchonine claim 1 , particularly wherein the chiral ligand is quinidine claim 1 , particularly wherein said chiral ligand is present in 2 to 3 molar equivalents in relation to compound 200.3. The method of claim 1 , wherein the Claisen rearrangement step proceeds in the presence of a strong non-nucleophilic base soluble in non-polar organic solvents claim 1 , particularly a lithium or potassium alkylamide or lithium or potassium silylalkylamide claim 1 , more particularly a base selected from LDA claim 1 , LiTMP and LiHMDS claim 1 , even more particularly in the presence of LiHMDS.4. The method of claim 1 , wherein Rand/or Ris/are CHF(CHF)CO— wherein n is 0 or 1 claim 1 , x is selected from 0 claim 1 , 1 claim 1 , 2 and 3 and y is selected from 0 claim 1 , 1 and 2 claim 1 , particularly Rand/or Ris/are selected from CFCO— claim 1 , CHFCO— claim 1 , CHFCO— claim 1 , CFCO and CFCFCO.5. The method of claim 1 , wherein the Claisen rearrangement step proceeds in the presence of LiHMDS and Ris CFCO—.6. The method of claim 1 , wherein Ris the same as Rand the enzymatic resolution step is performed directly after the Claisen rearrangement step.11. The method according to claim 7 , wherein{'sup': '1C', 'Ris a carboxylic acid moiety protecting group cleavable under acidic conditions,'}{'sup': 1', 'X', 'Y', 'Z', 'X', 'Y', 'Z, 'sub': 1', '4', '3', '6, 'particularly Ris —C(RRR) with R, Rand Rindependently selected from Cto Calkyl, Cto Ccycloalkyl or substituted or unsubstituted ...

Подробнее
11-01-2018 дата публикации

PHOTOLABILE ACETAL AND KETAL COMPOUNDS FOR THE CONTROLLED RELEASE OF ACTIVE VOLATILE CARBONYL COMPOUNDS

Номер: US20180010064A1
Автор: Herrmann Andreas
Принадлежит: FIRMENICH SA

The present invention relates to a delivery system based on photosensitive acetal or ketal compounds capable of liberating upon exposure to light an active volatile carbonyl compound in a controlled manner from a surface into the surrounding. The delivery system can be used to release active substances such as flavors, fragrances, malodor counteractants, insect attractants or insect repellents. The invention also relates to the use of said acetal or ketal compounds in perfumery, as well as in perfuming compositions or perfumed consumer articles. 2. The delivery system of claim 1 , wherein at least two Rand/or at least two Rare hydrogen atoms.3. The delivery system of claim 1 , wherein all of the groups Rand R claim 1 , which are not a hydrogen atom claim 1 , represent the same group selected from the group consisting of a linear C-Calkyl group claim 1 , a branched C-Calkyl group claim 1 , a methoxy group claim 1 , an ethoxy group claim 1 , a (OCHCH)OH group claim 1 , a (OCHCH)OCHgroup claim 1 , a methylthio group claim 1 , a dimethylamino group claim 1 , and a diethylamino group with n being an integer varying between 2 and 8.4. The delivery system of claim 1 , wherein the Rand Rgroup in ortho position with respect to the bond between the aromatic ring and the oxygenated ring are hydrogen atoms.5. The delivery system of claim 14 , wherein Rand Rare a hydrogen atom claim 14 , a methoxy group or a dimethylamino group.6. The delivery system of claim 1 , wherein Rrepresents a hydrogen atom claim 1 , a linear or branched C-Calkyl group claim 1 , a methoxy group claim 1 , a dimethylamino group or a diethylamino group.7. The delivery system of claim 1 , wherein the active volatile aldehyde or ketone is a perfuming ingredient.8. The delivery system of claim 7 , wherein the release of the perfuming compounds claim 7 , is triggered by light at a wavelength above 280 claim 7 , above 300 nm claim 7 , or above 330 nm.9. A perfuming composition comprising{'claim-ref': {'@idref': ...

Подробнее
14-01-2021 дата публикации

COMPOUNDS

Номер: US20210009576A1
Принадлежит:

The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated. 2. A compound according to claim 1 , or a salt or solvate thereof claim 1 , wherein X is O.3. (canceled)4. A compound according to claim 1 , or a salt or solvate thereof claim 1 , wherein M is selected from phenyl optionally substituted by one or more Rand a 5-6 membered heteroaryl optionally substituted by one or more R.5. (canceled)6. A compound according to claim 1 , or a salt or solvate thereof claim 1 , wherein M is selected from phenyl optionally substituted by one or more Rand pyridyl optionally substituted by one or more R.8. A compound according to claim 1 , or a salt or solvate thereof claim 1 , wherein Ris independently selected from hydroxyl claim 1 , ═O claim 1 , halogen claim 1 , CN claim 1 , Chaloalkyl claim 1 , Chaloalkoxy claim 1 , Calkyl claim 1 , O—Calkyl claim 1 , Ccycloalkyl claim 1 , 3-10 membered heterocycloalkyl claim 1 , —NRR claim 1 , and a group of Formula II as defined in .911-. (canceled)12. A compound according to claim 7 , or a salt or solvate thereof claim 7 , wherein Ris independently selected from ═O claim 7 , Calkyl claim 7 , O—Calkyl and —NRR.13. A compound according to claim 7 , or a salt or solvate thereof claim 7 , wherein Ris independently selected from a group of Formula II as defined in .1419-. (canceled)2122-. (canceled)23. A compound according to claim 20 , or a salt or solvate thereof claim 20 , wherein Ris hydrogen and x is 1.2430-. (canceled)31. A compound according to claim 1 , or a salt or solvate thereof claim 1 , wherein Ris selected from hydrogen claim 1 , Calkyl optionally substituted ...

Подробнее
11-01-2018 дата публикации

CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

Номер: US20180013076A1
Принадлежит:

Provided are a condensed cyclic compound having the following structure: 2. The condensed cyclic compound of claim 1 , wherein ring Dand ring Dare each independently selected from a benzene claim 1 , a naphthalene claim 1 , an anthracene claim 1 , a phenanthrene claim 1 , a chrysene claim 1 , and a pyrene.3. The condensed cyclic compound of claim 1 , wherein Lis selected from:a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an indacenylene group, an acenaphthylene group, a fluorenylene group, a spiro-bifluorenylene group, a benzofluorenylene group, a dibenzofluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, a pentaphenylene group, a hexacenylene group, a pentacenylene group, a rubicenylene group, a coronenylene group, a ovalenylene group, a pyrrolylene group, a thiophenylene group, a furanylene group, an imidazolylene group, a pyrazolylene group, a thiazolylene group, an isothiazolylene group, an oxazolylene group, an isoxazolylene group, a pyridinylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, an isoindolylene group, an indolylene group, an indazolylene group, a purinylene group, a quinolinylene group, an isoquinolinylene group, a benzoquinolinylene group, a phthalazinylene group, a naphthyridinylene group, a quinoxalinylene group, a quinazolinylene group, a cinnolinylene group, a phenanthridinylene group, an acridinylene group, a phenanthrolinylene group, a phenazinylene group, a benzimidazolylene group, a benzofuranylene group, a benzothiophenylene group, an isobenzothiazolylene group, a benzoxazolylene group, an isobenzoxazolylene group, a triazolylene group, a tetrazolylene group, an oxadiazolylene group, a triazinylene group, a dibenzofuranylene ...

Подробнее
03-02-2022 дата публикации

PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST

Номер: US20220033365A1
Принадлежит: QUÍMICA SINTÉTICA, S.A.

Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process. 2. The process according to claim 1 , wherein step a) is carried out in the absence of titanium-based Lewis acids.5. The process according to claim 4 , wherein the reaction between the indanone of general formula (1) and the compound of general formula (2A) is carried out in a solvent or a mixture of solvents in which the indanone of general formula (1) is soluble and the compound of general formula (3A) is insoluble.6. The process according to claim 1 , wherein steps a) and b) are carried out without isolating the compound of general formula (3).11. The process of claim 10 , wherein an additional step e′) is carried after step e) claim 10 , said step e′) comprising heating the mass resulting from the reaction between the compound of formula (8) and the amidoxime of formula (5) claim 10 , the tautomer or the salt thereof claim 10 , to a temperature from 50° C. to 120° C.12. The process according to claim 1 , wherein step b) is carried out under stereoselective reaction conditions.15. The process according to claim 13 , wherein the chiral ligand L is cyclohexylanisylmethylphosphine (CAMP) claim 13 , 1 claim 13 ,2-bis(anisylphenylphosphino)ethane (DIPAMP) claim 13 , 1 claim 13 ,2-bis(alkylmethylphosphino)ethane (BisP*) claim 13 , 2 claim 13 ,3-bis(diphenylphosphino)butane (CHIRAPHOS) claim 13 , 1 claim 13 ,2-bis(diphenylphosphino)propane (PROPHOS) claim 13 , 2 claim 13 ,3-bis(diphenylphosphino)-5-norbornene (NORPHOS) claim 13 , 2 claim 13 ,3-O-isopropylidene-2 claim 13 ,3-dihydroxy-1 claim 13 ,4-bis(diphenylphosphino)butane (DIOP) claim 13 , 1-cyclohexyl-1 claim 13 ,2-bis(diphenylphosphino)ethane (CYCPHOS) claim 13 , 1-substituted-3 claim 13 ,4-bis(diphenylphosphino)pyrrolidine (DEGPHOS) claim 13 , 2 claim 13 ,4-bis(diphenylphosphino)pentane (SKEWPHOS) claim 13 , 1 claim 13 ,2-bis(substituted-phospholano) ...

Подробнее
09-01-2020 дата публикации

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

Номер: US20200014066A1

This non-aqueous electrolyte secondary battery is provided with a positive electrode, a negative electrode and a non-aqueous electrolyte. The non-aqueous electrolyte contains: a non-aqueous solvent that contains a fluorine-containing cyclic carbonate; a cyclic carboxylic acid anhydride such as diglycolic acid anhydride; and an imide lithium salt having a sulfonyl group such as lithium bis(fluorosulfonyl)imide. 2. The non-aqueous electrolyte secondary battery according to claim 1 , wherein the cyclic carboxylic anhydride contains at least one of diglycolic anhydride claim 1 , methyldiglycolic anhydride claim 1 , dimethyldiglycolic anhydride claim 1 , ethyldiglycolic anhydride claim 1 , vinyldiglycolic anhydride claim 1 , allyldiglycolic anhydride claim 1 , and divinyldiglycolic anhydride.3. The non-aqueous electrolyte secondary battery according to claim 1 , wherein the imide lithium salt having sulfonyl groups contains at least one of lithium bis(fluorosulfonyl)imide claim 1 , lithium bis(trifluoromethanesulfonyl)imide claim 1 , lithium bis(pentafluoroethanesulfonyl)imide claim 1 , and lithium bis(nonafluorobutanesulfonyl)imide.4. The non-aqueous electrolyte secondary battery according to claim 1 , wherein the content of the fluorine-containing cyclic carbonate in the non-aqueous solvent is 5 vol % or more and 50 vol % or less.5. The non-aqueous electrolyte secondary battery according to claim 1 , wherein the content of the cyclic carboxylic anhydride in the non-aqueous electrolyte is 0.1 mass % or more and 1.5 mass % or less claim 1 , and the content of the imide lithium salt having sulfonyl groups in the non-aqueous electrolyte is 0.1 mass % or more and 1.5 mass % or less. The present invention relates to a technique concerning a non-aqueous electrolyte secondary battery.In recent years, a non-aqueous electrolyte secondary battery which includes a positive electrode, a negative electrode, and a non-aqueous electrolyte, and achieves charge and discharge by moving ...

Подробнее
21-01-2016 дата публикации

METHOD FOR PRODUCING LACTIDE DIRECTLY FROM LACTIC ACID AND A CATALYST USED THEREIN

Номер: US20160016151A1
Принадлежит:

The present invention provides a method for directly producing lactide by subjecting lactic acid to a dehydration reaction in the presence of a catalyst comprising a tin compound, preferably, a tin (IV) compound, wherein lactide can be produced directly or by one step from lactic acid, without going through the step of producing or separating lactic acid oligomer. The method of the present invention has advantages of causing no loss of lactic acid, having a high conversion ratio to lactic acid and a high selectivity to optically pure lactide, and maintaining a long life time of the catalyst. Further, since lactic acid oligomer is not or hardly generated and the selectivity of meso-lactide is low, the method also has an advantage that the cost for removing or purifying this can be saved.

Подробнее
17-01-2019 дата публикации

METHOD OF RECOVERING LACTIDE

Номер: US20190016696A1
Принадлежит: TOYO SEIKAN CO., LTD.

A method of recovering lactide which includes throwing a polylactic acid and a depolymerization catalyst into an extruder () communicated with a vent chamber () maintained under a reduced pressure, melt-kneading the polylactic acid and the depolymerization catalyst together in the extruder (), feeding the melt-kneaded product thereof into the vent chamber (), depolymerizing the polylactic acid in the vent chamber (), gasifying the formed lactide and recovering the gasified lactide from the vent chamber (). 1. A method of recovering lactide comprising throwing a polylactic acid and a depolymerization catalyst into an extruder , melt-kneading the polylactic acid and the depolymerization catalyst together in said extruder , feeding said melt-kneaded product thereof from said extruder into a vent chamber maintained under a reduced pressure , depolymerizing the polylactic acid in said vent chamber , gasifying the formed lactide therein , and recovering the gasified lactide from said vent chamber.2. The method of recovering lactide according to claim 1 , wherein the polylactic acid and the polymerization catalyst are thrown into said extruder hut without throwing the carrier resin therein claim 1 , and the melt-kneaded product of said polylactic acid is fed into said vent chamber without using the carrier resin.3. The method of recovering lactide according to claim 1 , wherein a trapping apparatus is linked to said vent chamber to trap the gasified lactide.4. The method of recovering lactide according to claim 1 , wherein said vent chamber is provided at the bottom portion thereof with a discharge pipe for discharging the residue from which the gasified lactide has been removed.5. The method of recovering lactide according to claim 1 , wherein said depolymerization catalyst is thrown into said extruder on the side downstream of the polylactic acid in the direction of extrusion in the extruder.6. The method of recovering lactide according to claim 1 , wherein the ...

Подробнее
21-01-2021 дата публикации

Method for producing glycolide

Номер: US20210017146A1
Принадлежит: Kureha Corp

The method for producing glycolide that achieves the object described above includes: an oligomer preparation step of heating an aqueous glycolic acid solution and subjecting glycolic acid contained in the aqueous glycolic acid solution to dehydrating polycondensation, to obtain a glycolic acid oligomer; and a depolymerization step of depolymerizing the glycolic acid oligomer in the presence of ferrous ions to obtain glycolide.

Подробнее
28-01-2016 дата публикации

NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION

Номер: US20160024004A1
Принадлежит:

The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections. 45-. (canceled)6. The compound of claim 1 , wherein{'sup': '3', 'Ris selected from the group consisting of optionally substituted aryl, optionally substituted benzyl, optionally substituted alkylaryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; and'}{'sup': '4', 'where present, Ris hydrogen.'}7. The compound of claim 6 , wherein{'sup': '3', 'Ris selected from a group consisting of optionally substituted phenyl, optionally substituted benzyl, optionally substituted benzoisoxazolyl, optionally substituted benzooxazolyl, optionally substituted furyl, optionally substituted imidazolyl, optionally substituted indoyl, optionally substituted isoxazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl, optionally substituted pyrazolyl, optionally substituted pyridin-2-on-yl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted quinolinyl, optionally substituted thiazolyl optionally substituted thienyl, and optionally substituted methylpyridyl.'}9. The compound of claim 7 , wherein the optional substitution of Rcomprises at least one halo or Calkyl.10. (canceled)12. The compound of claim 1 , wherein{'sup': 5', '7, 'Rand Rare independently at each occurrence H or F; and'}{'sup': 6', '8, 'sub': 1-3', '1-3, 'Rand Rare independently at each occurrence hydrogen, chloro, fluoro, Calkyl, or Calkoxy.'}14. The compound of claim 1 , wherein{'sup': 5', '7', '8, 'R, R, and Rare each H; and'}{'sup': '6', 'Ris hydrogen, chloro, ...

Подробнее
28-01-2016 дата публикации

Prodrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae

Номер: US20160024042A1
Принадлежит:

Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition. 2. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.3. The compound of wherein Ris selected from mono- and polyfluoro-substituted arylalkyl moieties.4. The compound of wherein Ris selected from mono- and difluoro-substituted benzyl moieties.5. The compound of in at least one of human plasma and contact with an enzyme in a streptococcal mevalonate biosynthetic pathway.7. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.8. The compound of wherein Ris selected from aryl claim 7 , mono- and polyfluoroaryl claim 7 , arylalkyl claim 7 , mono- and polyfluoroarylalkyl moieties.9. The compound of wherein Ris selected from phenyl claim 8 , mono- and polyfluorophenyl claim 8 , benzyl claim 8 , monofluorobenzyl and polyfluorobenzyl moieties.11. The compound of wherein X is selected from NH and O; and Ris independently selected from fluoromethyl and trifluoromethyl moieties.12. The compound of where Ris selected from arylalkyl claim 11 , mono- and polyfluoro-substituted arylalkyl moieties.13. The compound of wherein Rand Rare independently selected from H and alkyl moieties.14. The compound of wherein at least one of Rand Ris methyl.16. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.17. The compound of wherein Ris selected from alkyl claim 16 , mono- and polyfluoro-substituted alkyl claim 16 , aryl claim 16 , mono- and polyfluoro-substituted aryl claim 16 , arylalkyl claim 16 , mono- and polyfluoro-substituted arylalkyl moieties.18. The compound of wherein X is O; Ris selected from alkyl claim 15 , aryl and arylalkyl moieties; and Rand Rare independently selected from H and acetyl moieties.19. The compound of wherein at least one of Rand Ris acetyl.21. The compound of ...

Подробнее
28-01-2016 дата публикации

Process and Apparatus for Purification of a Stream Containing a Cyclic Ester of an Alpha-Hydroxycarboxylic Acid

Номер: US20160024043A1
Принадлежит:

The invention relates to a process for purification of a stream containing a cyclic ester of an alpha-hydroxycarboxylic acid of formula (I), wherein each R independently represents hydrogen or an aliphatic hydrocarbon having 1 to 6 carbon atoms comprising the steps of: (a) separating the cyclic ester-containing stream into one or more cyclic ester-containing vapour fractions and one or more cyclic ester-containing liquid fractions; (b) condensing a cyclic ester-containing vaporized fraction as obtained in step (a) to obtain a cyclic ester-containing condensate; (c) subjecting at least part of the cyclic ester-containing condensate as obtained in step (b) to melt crystallization to obtain a purified cyclic ester-containing stream and a residue stream; and (d) recovering the purified cyclic ester-containing stream as obtained in step (c). The invention further relates to an apparatus suitable for carrying out the present process. 122-. (canceled)24. The process according to claim 23 , wherein the cyclic ester is lactide.25. The process according to claim 23 , wherein the cyclic ester-containing condensate is undercooled in step (b) 5 to 10° C. above its freezing point before it is subjected to melt crystallization in a step (c).26. The process according to claim 23 , wherein step (a) is carried out in a distillation column.27. The process according to claim 26 , wherein the cyclic ester-containing vapour fraction to be condensed in step (b) is withdrawn from the distillation column via a side draw and introduced into a condensation unit.28. The process according to claim 26 , wherein a cyclic ester-containing liquid fraction as obtained in step (a) is subjected to a first evaporation treatment to obtain a first cyclic ester-containing vapour stream and a first cyclic ester-containing liquid stream claim 26 , and wherein the cyclic ester-containing vapour fraction which is to be condensed in step (b) is at least partly derived from the first cyclic ester-containing ...

Подробнее
28-01-2016 дата публикации

INHIBITING NEUROTRANSMITTER REUPTAKE

Номер: US20160024044A1
Принадлежит:

This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. Specifically gamma-amino alcohol derivatives that inhibit the reuptake of neurotransmitters such as dopamine, serotonin, epinephrine or norepinephrine are provided as therapeutic agents for the treatment of depression or anxiety in a mammalian subject. 17-. (canceled)9. The compound of claim 8 , wherein Ris optionally substituted with one or two substituents.11. The compound of claim 10 , wherein at least two of R claim 10 , R claim 10 , R claim 10 , R claim 10 , and Rare hydrogen.12. The compound of claim 11 , wherein the remaining R claim 11 , R claim 11 , R claim 11 , R claim 11 , and Rare independently selected from ethyl claim 11 , chloro claim 11 , and bromo.13. The compound of claim 10 , wherein R claim 10 , R claim 10 , and Rare hydrogen; and Rand Rare independently selected from ethyl claim 10 , chloro claim 10 , and bromo.15. The compound of claim 14 , wherein each of Rand Ris not hydrogen.17. The compound of claim 16 , wherein Ris selected from hydrogen claim 16 , lower alkyl claim 16 , halo claim 16 , hydroxyl claim 16 , lower alkoxy claim 16 , methylsulfanyl claim 16 , and methsulfonyl; and Ris selected from hydrogen claim 16 , lower alkyl claim 16 , halo claim 16 , dimethylamino claim 16 , methylsulfanyl claim 16 , and 1 claim 16 ,1 claim 16 ,1-trifluoromethanesulfonamide.1826-. (canceled) This application claims the benefit of U.S. Provisional Application Ser. No. 61/783,122, filed Mar. 14, 2013. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.1. Technical FieldThis document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake.2. Background InformationNeuronal signals are ...

Подробнее
22-01-2015 дата публикации

Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia

Номер: US20150024032A1
Принадлежит: Baylor College of Medicine

Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.

Подробнее
25-01-2018 дата публикации

KETAL COMPOUNDS AND USES THEREOF

Номер: US20180022724A1
Автор: Bechtold Kevin Jon
Принадлежит:

Various esterified alkyl ketal ester or hydroxyalkyl ketal ester products are useful as components of organic polymer compositions. The ketal esters are produced in certain transesterifications between alkyl ketal esters and/or hydroxyalkyl ketal esters and polyols, aminoalcohols, polyamines and/or polycarboxylic acids. The products are excellent plasticizers for a variety of organic polymers, notable poly(vinylchloride) plastisols. 2. The compound of claim 1 , wherein Rcontains one or more ether or ester groups.3. The compound of claim 1 , wherein Ris C-Calkyl.5. A mixture comprising two or more compounds of .6. A composition comprising the compound of claim 1 , and an organic polymer.7. The composition of claim 6 , which has a glass transition temperature at least 30° C. lower than a glass transition temperature of the polymer.8. The composition of claim 6 , wherein the compound constitutes from 0.1 to 90% of the combined weight of the compound and the polymer.9. The composition of claim 6 , wherein the polymer is a thermoplastic.10. The composition of claim 6 , wherein the polymer is a thermoset.11. The composition of claim 6 , wherein the polymer comprises a poly(vinyl chloride) claim 6 , polyhydroxyalkanoate claim 6 , a poly(lactic acid) claim 6 , a polystyrene claim 6 , a polyurethane claim 6 , a polyurea claim 6 , a polyurea-urethane claim 6 , a polycarbonate claim 6 , an acrylic polymer claim 6 , a styrene-acrylic polymer claim 6 , a vinyl-acrylic polymer claim 6 , an ethylene-vinyl acetate polymer claim 6 , a polyester claim 6 , a polyamide claim 6 , a polyether claim 6 , a polybutadiene claim 6 , an acrylonitrile-butadiene-styrene copolymer claim 6 , a styrene-butadiene-styrene copolymer claim 6 , a polyvinyl acetate claim 6 , an elastomer claim 6 , or homopolymers thereof claim 6 , or random claim 6 , graft claim 6 , or block copolymers thereof claim 6 , or blends or mixtures thereof.12. The composition of claim 6 , wherein the compound is melt blended or ...

Подробнее
25-01-2018 дата публикации

SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS

Номер: US20180022757A1
Принадлежит:

Methods of making compounds of Formula I are disclosed: 1123-. (canceled)125. The process of wherein B-1 is reacted with J-1 in the presence of an acid selected from the group consisting of an inorganic acid claim 124 , an organic acid claim 124 , a halogenated organic acid claim 124 , and mixtures thereof.126. The process of wherein the acid is selected from the group consisting of hydrochloric acid claim 125 , hydrobromic acid claim 125 , hydroiodic acid claim 125 , trifluoromethanesulfonic acid claim 125 , formic acid claim 125 , trifluoroacetic acid claim 125 , trichloroacetic acid claim 125 , perfluoropropionic acid claim 125 , and a mixture thereof.127. The process of wherein the acid is trifluoroacetic acid.128. The process of any one of to claim 126 , wherein J-1 is in the form of a salt or co-crystal.129. The process of any one of to wherein Hal is F.133145-. (canceled)147152-. (canceled)154193-. (canceled)195. The process of wherein the acid is selected from the group consisting of an inorganic acid claim 194 , an organic acid claim 194 , a halogenated organic acid claim 194 , a Lewis acid and mixtures thereof.196. The process of any one of to wherein the acid is selected from the group consisting of hydrochloric acid claim 194 , hydrobromic acid claim 194 , hydroiodic acid claim 194 , trifluoromethanesulfonic acid claim 194 , formic acid claim 194 , trifluoroacetic acid claim 194 , trichloroacetic acid claim 194 , perfluoropropionic acid claim 194 , dichloroacetic acid claim 194 , chloroacetic acid claim 194 , acetic acid claim 194 , para-toluenesulfonic acid claim 194 , methane sulfonic acid claim 194 , zinc chloride claim 194 , magnesium bromide claim 194 , magnesium triflate claim 194 , copper triflate claim 194 , scandium triflate claim 194 , and a mixture thereof.197. The process of any one of to wherein the acid is trifluoroacetic acid.198242-. (canceled) This application claims priority to and the benefit of U.S. Provisional Application No. 62/015, ...

Подробнее
25-01-2018 дата публикации

COMPOUND HAVING ALKOXY GROUP OR ALKOXYALKYL GROUP, AND SATURATED SIX-MEMBERED RING, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE

Номер: US20180022999A1
Автор: Ookawa Hiroki
Принадлежит:

Provided is a liquid crystal compound satisfying at least one of physical properties such as high stability to heat, light or the like, a high clearing point, low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy and large dielectric anisotropy, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. 2. (canceled)4. The liquid crystal composition according to claim 1 , wherein a is 1.5. (canceled)6. (canceled)8. (canceled)10. (canceled)13. The liquid crystal composition according to claim 1 , further containing at least one of a polymerizable compound claim 1 , an optically active compound claim 1 , an antioxidant claim 1 , an ultraviolet light absorber claim 1 , a light stabilizer claim 1 , a heat stabilizer and an antifoaming agent.15. (canceled)17. The liquid crystal composition according to claim 14 , wherein a is 1.18. (canceled)19. (canceled)21. (canceled)25. The liquid crystal composition according to claim 14 , having a chiral nematic phase in a temperature of any of −20° C. to 70° C. claim 14 , wherein a helical pitch is 700 nanometers or less in at least part of the range of the temperature.26. The liquid crystal composition according to claim 14 , used for a device driven in an optically isotropic liquid crystal phase.27. A polymer-liquid crystal composite material claim 24 , obtained by polymerizing the liquid crystal composition according to and used for a device driven in an optically isotropic liquid crystal phase.28. An optical device claim 24 , having an electrode arranged on one or both substrates claim 24 , a liquid crystal medium arranged between the substrates claim 24 , and an electric field applying means for applying an electric field to the liquid crystal medium through the electrode claim 24 , wherein the optical device is prepared by using the liquid crystal composition according to as the liquid crystal medium claim 24 , or comprises a ...

Подробнее